

Supporting Information

for

Synthesis of new tetra- and pentacyclic, methylenedioxy- and ethylenedioxy-substituted derivatives of the dibenzo[c,f][1,2]thiazepine ring system

Gábor Berecz, András Dancsó, Mária Tóthné Lauritz, Loránd Kiss, Gyula Simig and Balázs Volk

Beilstein J. Org. Chem. 2025, 21, 2645-2656. doi:10.3762/bjoc.21.205

Experimental procedures and characterization of compounds 6, 10–19, 20a–e, 21c–p, 23a–e, 24, 26–28, 30–37, 38a–d, 39–44, 45a–c, 46–53, 54a–f. ¹H and ¹³C NMR spectra of all new compounds. 2D NMR spectra of compounds 6–8, 12, 21a, 21b, 25–27, 30, 32, 38b, 42, 50, 51, 54e

Table of contents

experimental procedures and characterization of compounds 6, 10-19, 20a-e, 21c-p,	
23a-e, 24, 26-28, 30-37, 38a-d, 39-44, 45a-c, 46, 48-53, 54a-f	S2
¹ H and ¹³ C NMR spectra of compounds 6–8 , 10–19 , 20a–e , 21a–p , 23a–e , 24–37 ,	
38a-d, 39-43, 45a-c, 46, 48-53, 54a-f (including 2D NMR spectra of	
compounds 6-8, 12, 21a, 21b, 25-27, 30, 32, 38b, 42, 50, 51, 54e)	S39

Methyl 2-(1,3-benzodioxol-5-ylsulfamoyl)-4-chlorobenzoate (10). To a vigorously stirred solution of 1,3-benzodioxol-5-amine (14.40 g, 105 mmol) and N,N-diethylaniline (15.67 g, 105 mmol, 16.7 mL) in MeOH (150 mL), methyl 4-chloro-2-chlorosulfonylbenzoate (9, 26.91 g, 100 mmol) was added over a period of 5 min while cooling the reaction mixture with tap water. It was stirred at room temperature for 1 h and at 0-5 °C for 1 h. The crystalline product separated was filtered and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, DCM). After evaporation of the solvents, the solid residue was triturated with MeOH, filtered and airdried to afford 10 (35.10 g, 95%) as colorless crystals. M. p. 166.5-168.5 °C (CH₃CN). IR (KBr): 3227, 1713, 1292, 1171, 1031, 690 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 10.05 (br s, 1H), 7.86 (d, ${}^{4}J$ = 2.1 Hz, 1H), 7.79 (dd, ${}^{4}J$ = 2.1 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 7.68 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.82 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.68 (d, ${}^{4}J$ = 2.2 Hz, 1H), 6.53 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 5.99 (s, 2H), 3.83 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d*₆): 166.72, 147.71, 145.10, 138.78, 135.52, 133.08, 131.35, 131.04, 130.51, 128.25, 115.57, 108.50, 104.13, 101.63, 53.31. MS (EI): $M^{+}=369$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{15}H_{13}CINO_6S$ $[M+H]^{+}$: 370.0146, found: 370.0151.

Methyl 4-chloro-2-(2,3-dihydro-1,4-benzodioxin-6-ylsulfamoyl)benzoate (11). To a vigorously stirred solution of 2,3-dihydro-1,4-benzodioxin-6-amine (29.03 g, 192 mmol) and N,N-diethylaniline (28.65 g, 192 mmol, 30.6 mL) in MeOH (300 mL), methyl 4-chloro-2chlorosulfonylbenzoate (9, 50.05 g, 186 mmol) was added over a period of 10 min while cooling the reaction mixture with tap water. An exothermic reaction took place, and the product started to crystallize. The brown suspension was stirred at room temperature for 1 h, then at 0-5 °C for 1 h. The crystalline product was filtered and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM). After evaporation of the solvent, the solid residue was triturated with MeOH, filtered and air-dried to afford 11 (66.0 g, 92%) as colorless crystals. M. p. 153-154 °C (MeOH). IR (KBr): 3266, 1715, 1504, 1175 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 7.96 (br s, 1H), 7.83 (d, ${}^{4}J$ = 1.8 Hz, 1H), 7.80 (d, ${}^{3}J$ = 7.7 Hz, 1H), 7.54 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.4 Hz, 1H), 6.70 (d, ${}^{3}J$ = 8.4 Hz, 1H), 6.70 (d, ${}^{4}J$ = 2.6 Hz, 1H), 6.59 (dd, ${}^{4}J$ = 2.6 Hz, ${}^{3}J$ = 8.8 Hz, 1H), 4.20 (s, 4H), 4.02 (s, 3H). ¹³C NMR (50 MHz, CDCl₃): 167.26, 143.60, 142.25, 140.17, 138.18, 132.42, 132.15, 130.64, 129.27, 128.45, 117.48, 116.99, 113.12, 64.21, 64.11, 53.63. MS (ESI): [M- $H^{-} = 382$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{16}H_{15}CINO_6S$ [M+H]⁺: 384.0303, found: 384.0309.

Methyl 2-[1,3-benzodioxol-5-yl(methyl)sulfamoyl]-4-chlorobenzoate (12). To a solution of compound **10** (31.08 g, 84 mmol) in DMF (75 mL), anhydrous K₂CO₃ (15.20 g, 110 mmol) was added. To the vigorously stirred suspension iodomethane (15.61 g, 110 mmol, 6.9 mL) was added dropwise and the reaction mixture was stirred at room temperature for 4 h. Water (450 mL) was added and a thick oil separated. The supernatant was decanted, the oil was dissolved in DCM (100 mL), the solution was washed with water (2 × 100 mL), the organic phase was dried over Na₂SO₄ and evaporated in vacuo. The residual dense orange oil was dissolved in a heptane/DCM mixture 2:1 (150 mL), silica gel (20 g, Kieselgel 60 H) was added, and it was stirred at room temperature for 30 min. The filtrate was evaporated in vacuo to afford 12 (31.4 g of dense yellow oil, yield 97%). The TLC pure intermediate was transformed in the next step without further purification. IR (film): 1739, 1484, 1354, 1292, 1253, 1162, 1120, 1057, 1037, 940, 836 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 7.56 (dd, ${}^{4}J$ = 2.1 Hz, ${}^{3}J$ = 8.2 Hz, 1H), 7.46 (d, ${}^{4}J$ = 2.0 Hz, 1H), 7.44 (d, ${}^{3}J$ = 8.2 Hz, 1H), 6.73 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.72 (d, ${}^{4}J$ = 2.2 Hz, 1H), 6.60 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 6.00 (s, 2H), 3.89 (s, 3H), 3.26 (s, 3H). ¹³C NMR (150 MHz, CDCl₃): 167.44, 147.94, 147.29, 136.96, 135.97, 134.40, 132.44, 131.66, 129.92, 129.51, 121.11, 109.04, 108.07, 101.74, 53.27, 39.43. COSY: 7.46–7.56–7.44, 6.73– 6.60-6.72. HSQC (140 Hz): 7.56-132.44, 7.46-129.92, 7.44-129.51, 6.73-108.07, 6.72-109.04, 6.60–121.11, 6.00–101.72, 3.89–53.27, 3.26–39.43. HMBC (8 Hz, 140 Hz): 7.56– 131.66, 7.46–(135.97, 132.44, 131.66), 7.44–(167.44, 136.96, 135.97), 6.73–(147.94, 134.40), 6.72-(147.29, 121.11), 6.60-(147.29, 109.04), 6.00-(147.94, 147.29), 3.89-167.44, 3.26-134.40. HRMS (ESI): m/z calcd. for C₁₆H₁₅ClNO₆S [M+H]⁺: 384.0304, found: 384.0307.

 1H), 7.43 (d, ${}^{4}J$ = 2.2 Hz, 1H), 6.80 (d, ${}^{3}J$ = 8.8 Hz, 1H), 6.72 (d, ${}^{4}J$ = 2.6 Hz, 1H), 6.65 (dd, ${}^{4}J$ = 2.6 Hz, ${}^{3}J$ = 8.8 Hz, 1H), 4.25 (s, 4H), 3.87 (s, 3H), 3.24 (s, 3H). ${}^{13}C$ NMR (50 MHz, CDCl₃): 167.39, 143.48, 143.33, 136.98, 135.85, 133.80, 132.32, 131.64, 129.83, 129.45, 120.53, 117.31, 116.71, 64.26, 64.16, 53.16, 39.13. MS (GC-EI): M^{+} = 397 (1 Cl). HRMS (ESI): m/z calcd. for $C_{17}H_{17}CINO_6S$ [M+H]⁺: 398.0459, found: 398.0467.

2-[1,3-Benzodioxol-5-yl(methyl)sulfamoyl]-4-chlorobenzoic acid (14). A solution of NaOH (8.00 g, 200 mmol) in water (150 mL) was added to the solution of compound **12** (30.70 g, 80 mmol) in MeOH (150 mL) and it was refluxed for 1 h. Water (750 mL) was added, the solution was cooled with ice-water, and an aqueous HCl solution (5%, 150 mL, 205 mmol HCl) was added in 20 min (pH 1). The colorless suspension obtained was stirred for 30 min while cooling with ice-water, it was filtered, washed with water, and dried over P_2O_5 to afford **14** (28.6 g, 97%) as off-white crystals. M. p. 153–155 °C (CH₃CN, colorless crystals). IR (KBr): 2700, 1706, 1337, 844 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 13.7 (br s, 1H), 7.81 (dd, ⁴J = 2.0 Hz, ³J = 8.2 Hz, 1H), 7.66 (d, ³J = 8.2 Hz, 1H), 7.32 (d, ⁴J = 1.8 Hz, 1H), 6.88 (d, ³J = 8.2 Hz, 1H), 6.82 (d, ⁴J = 1.9 Hz, 1H), 6.64 (dd, ⁴J = 2.2 Hz, ³J = 8.2 Hz, 1H), 6.06 (s, 2H), 3.19 (s, 3H). ¹³C NMR (125 MHz, DMSO- d_6): 168.03, 147.63, 146.92, 135.70, 134.34, 134.08, 133.88, 133.26, 130.22, 128.85, 121.00, 108.70, 108.20, 101.93, 39.14. MS (EI): M = 369 (1 Cl). HRMS (ESI): m/z calcd. for $C_{15}H_{13}$ ClNO₆S [M+H]⁺: 370.0146, found: 370.0146.

4-Chloro-2-[2,3-dihydro-1,4-benzodioxin-6-yl(methyl)sulfamoyl]benzoic acid (15). A solution of NaOH (11.80 g, 295 mmol) in water (200 mL) was added to the suspension of compound **13** (46.94 g, 118 mmol) in MeOH (200 mL) and the mixture was refluxed for 1 h. The solution obtained was diluted with water (750 mL), cooled with ice-water, and an aqueous HCl solution (5%, 225 mL, 308 mmol HCl) was added in 20 min (pH 1). The partly oily product separated was stirred at room temperature for 3 h. The suspension obtained was filtered, washed thoroughly with water (3 × 100 mL), and dried over P₂O₅ to afford **15** (44.8 g, 99%) as off-white crystals. M. p. 156–158 °C (CH₃CN, colorless crystals). IR (KBr): 3251, 1740, 1504, 1337, 1232, 1065 cm⁻¹. ¹H NMR (200 MHz, DMSO- d_6): 13.68 (br s, 1H), 7.81 (dd, ⁴J = 1.8 Hz, ³J = 8.2 Hz, 1H), 7.67 (d, ³J = 8.2 Hz, 1H), 7.29 (d, ⁴J = 1.8 Hz, 1H), 6.85 (d, ³J = 8.5 Hz, 1H), 6.73 (d, ⁴J = 2.1 Hz, 1H), 6.65 (dd, ⁴J = 2.4 Hz, ³J = 8.6 Hz, 1H), 4.24 (s, 4H), 3.19 (s, 3H). ¹³C NMR (50 MHz, DMSO- d_6): 168.05, 143.40, 143.23, 135.82, 134.16, 133.69, 133.63, 133.24, 130.22, 128.83, 120.15, 117.31, 116.39, 64.23, 38.97. MS (EI): M⁺ = 383 (1 Cl). HRMS (ESI): m/z calcd. for C₁₆H₁₅ClNO₆S [M+H]⁺: 384.0303, found: 384.0310.

8-Chloro-5-methyl[1,3]benzodioxolo[5,6-c]benzo[f][1,2]thiazepin-11(5H)-one 6,6-dioxide (6). To the suspension of 14 (24.04 g, 65 mmol) in DCM (200 mL), PCl₅ (16.24 g, 78 mmol) was added in portions, and the solution obtained was refluxed for 8.5 h. It was cooled to 0-5 °C, and SnCl₄ (37.25 g, 143 mmol, 16.7 mL) was added dropwise over a period of 10 min. The thick suspension obtained was stirred at 0-5 °C for 2 h, then it was allowed to warm to room temperature. The orange suspension was poured onto a mixture of crushed ice (600 g) and conc hydrochloric acid (50 mL) and DCM (100 mL). The mixture was stirred until warming to room temperature (1 h), the product separated was filtered, washed with diluted hydrochloric acid (5%, 2×50 mL) and water (2×50 mL), and air-dried to give crude 6 (17.17 g of yellow solid). The two-phase filtrate was separated, the strongly acidic aqueous phase was washed with DCM (2 × 50 mL), the combined organic phases were washed with water (100 mL), dried over Na₂SO₄, evaporated, and the oily residue was triturated with ether (50 mL) to afford a second crop of 6 (1.94 g of brown solid). The two crops were purified by dry-column flash chromatography on a short silica gel column (thickness of the stationary phase: 30 mm, eluent: DCM). After evaporation of the solvent, the residue was triturated with Et₂O (50 mL) to give 6 (17.34 g, 76%) as pale yellow crystals. M. p. 268–271 °C (CH₃CN, decomp.). IR (KBr): 1639, 1623, 1482, 1353, 1245, 1033 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 8.01 (d, ${}^{3}J$ = 8.4 Hz, 1H), 7.95 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.74 (s, 1H), 7.67 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.4 Hz, 1H), 6.79 (s, 1H), 6.11 (s, 2H), 3.24 (s, 3H). ¹³C NMR (150 MHz, CDCl₃): 186.97, 153.31, 147.00, 138.76, 137.99, 137.95, 133.99, 133.81, 133.18, 126.34, 125.87, 109.94, 105.60, 102.88, 39.38. COSY: 8.01-7.67-7.95. HSQC (140 Hz): 8.01-133.99, 7.95-125.878, 7.74-109.94, 7.67-133.18, 6.79–105.60, 6.11–102.88, 3.24–39.38. HMBC (8 Hz, 140 Hz): 8.01–(186.97, 138.76, 137.99), 7.95–(133.81, 133.18), 7.74–(186.97, 153.31, 137.95), 7.67–(133.81, 125.87), 6.79–(153.31, 147.00, 137.95, 126.34), 6.11–(153.31, 147.00), 3.24–137.95. MS (EI): M^+ = 351 (1 Cl). HRMS (ESI): m/z calcd. for C₁₅H₁₁ClNO₅S [M+H]⁺: 352.0041, found: 352.0043.

8-Chloro-5-methyl-5,11-dihydro[1,3]benzodioxolo[5,6-*c*]**benzo[***f*][1,2]**thiazepin-11-ol 6,6-dioxide (16).** To a suspension of **6** (7.04 g, 20 mmol) in DMF (100 mL) and EtOH (100 mL), NaBH₄ (1.51 g, 40 mmol) was added, and the reaction mixture was stirred at room temperature for 4.5 h. Water (800 mL) was added dropwise in 30 min. The separated product was filtered, washed with water, and dried in vacuo over P₂O₅ to give **16** (6.72 g, 95%) as colorless crystals. M. p. decomp. from 200 °C (CH₃CN). IR (KBr): 3452, 1503, 1481, 1308, 1141, 1036 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 7.86 (dd, 4J = 0.6 Hz, 3J = 8.7 Hz, 1H), 7.76 (d, 4J = 2.2 Hz, 1H), 7.70 (dd, 4J = 2.2 Hz, 3J = 8.4 Hz, 1H), 7.18 (s, 1H), 7.04 (s, 1H), 6.60 (d, 3J = 5.0 Hz, 1H), 6.16 (d, 3J = 4.9 Hz, 1H), 6.09 (d, 4J = 1.0 Hz, 1H), 6.04 (d, 4J = 1.0 Hz, 1H), 3.37 (s, 3H).

¹³C NMR (125 MHz, DMSO- d_6): 147.58, 147.33, 140.39, 139.82, 138.34, 132.83, 132.12, 129.01, 128.07, 126.66, 108.70, 105.10, 102.15, 67.51, 37.20. MS (EI): M⁺ = 353 (1 Cl). HRMS (ESI): m/z calcd. for C₁₅H₁₂ClNNaO₅S [M+Na]⁺: 376.0017, found: 376.0022.

9-Chloro-6-methyl-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepin-12-ol 7,7-dioxide (17). To a suspension of 7 (15.00 g, 41 mmol) in DMF (100 mL) and EtOH (100 mL), NaBH₄ (3.10 g, 82 mmol) was added, and the reaction mixture was stirred at room temperature for 23 h. Water (800 mL) was added dropwise in 30 min. The product separated was filtered, washed with water, and dried in vacuo over P₂O₅ to give **17** (14.75 g, 98%) as colorless crystals. M. p. decomp. from 180 °C (CH₃CN). IR (KBr): 3531, 1500, 1303, 1134, 1064 cm⁻¹. ¹H NMR (200 MHz, DMSO- d_6): 7.85 (d, 3J = 8.4 Hz, 1H), 7.75 (d, 4J = 1.8 Hz, 1H), 7.70 (dd, 4J = 2.2 Hz, 3J = 8.4 Hz, 1H), 7.05 (s, 1H), 7.02 (d, 4J = 0.7 Hz, 1H), 6.53 (d, 3J = 3.3 Hz, 1H), 6.10 (bd, 4J = 2.6 Hz, 1H), 4.24 (s, 4H), 3.33 (s, 3H). ¹³C NMR (50 MHz, DMSO- d_6): 143.53, 143.23, 140.34, 139.44, 136.21, 132.76, 132.23, 128.95, 128.65, 126.67, 117.01, 114.25, 67.95, 64.33, 64.24, 37.88. MS (EI): M⁺ = 367 (1 Cl). HRMS (ESI): m/z calcd. for C₁₆H₁₄CINNaO₅S [M+Na]⁺: 390.0173, found: 390.0176.

8,11-Dichloro-5-methyl-5,11-dihydro[1,3]benzodioxolo[5,6-c]benzo[f][1,2]thiazepine 6,6-dioxide (18). To a vigorously stirred suspension of 16 (6.19 g, 17.5 mmol) in DCM (40 mL), SOCl₂ (1.52 mL, 2.50 g, 21 mmol) was added dropwise at room temperature. The solution obtained was stirred at room temperature for 1.5 h, then evaporated in vacuo. The residue was triturated with DIPE (20 mL), filtered and dried in vacuo to give crude 18 (6.51 g, 100%) as colorless crystals. M. p. decomp. from 164 °C. The product is of suitable quality for use in the next step. IR (KBr): 1503, 1490, 1340, 1229, 1031 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.96 (d, ${}^{4}J$ = 2.1 Hz, 1H), 7.48 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 7.42 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.94 (s, 1H), 6.82 (s, 1H), 6.06 (d, ${}^{4}J$ = 1.4 Hz, 1H), 6.02 (d, ${}^{4}J$ = 1.3 Hz, 1H), 5.98 (s, 1H), 3.52 (s, 3H). 13 C NMR (125 MHz, CDCl₃): 149.78, 147.65, 141.50, 136.17, 133.54, 133.11, 132.49, 132.33, 131.19, 127.89, 109.51, 108.97, 102.53, 63.30, 38.98. MS (EI): ${\rm M}^{+}$ = 371 (2 Cl). HRMS (TOF MS EI): ${\rm m/z}$ calcd. for [C₁₅H₁₁Cl₂NO₄S]⁺: 370.9786, found: 370.9796.

9,12-Dichloro-6-methyl-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepine 7,7-dioxide (19). To a vigorously stirred suspension of 17 (14.71 g, 40 mmol) in DCM (80 mL), SOCl₂ (3.5 mL, 5.71 g, 48 mmol) was added dropwise at room temperature. The solution obtained was stirred at room temperature for 3.5 h. Hexane (240 mL) was added to the suspension formed, the product was filtered, washed with hexane (2 × 30 mL) and dried in vacuo to give crude 19 (14.50 g, 94%) as colorless crystals. M. p. decomp. from 160 °C. The product is of suitable quality for use in the next step. IR (KBr): 1512, 1327, 1142,

1065 cm⁻¹. ¹H NMR (200 MHz, CDCl₃): 7.97 (d, ⁴J = 1.8 Hz, 1H), 7.48 (dd, ⁴J = 2.0 Hz, ³J = 8.4 Hz, 1H), 7.43 (d, ³J = 8.4 Hz, 1H), 7.02 (s, 1H), 6.90 (s, 1H), 5.99 (s, 1H), 4.26 (s, 4H), 3.52 (s, 3H). ¹³C NMR (50 MHz, CDCl₃): 145.42, 143.38, 141.71, 136.08, 133.52, 132.69, 132.32, 132.11, 130.27, 127.98, 118.30, 118.25, 64.32, 64.25, 63.39, 39.26. MS (EI): M⁺ = 385 (2 Cl). HRMS (TOF MS EI): m/z calcd. for [C₁₆H₁₃Cl₂NO₄S]⁺: 384.9942, found: 384.9945.

Ethyl 7-[(8-chloro-5-methyl-6,6-dioxido-5,11-dihydro[1,3]benzodioxolo[5,6-

c]benzo[f][1,2]thiazepin-11-yl)amino]heptanoate (20a). To a solution of ethyl 7-aminoheptanoate (2.77 g, 16 mmol) in CH₃CN (15 mL) crude **18** (2.60 g, 7 mmol) was added, the solution obtained in 5 min was stirred at room temperature for 1 h. It was evaporated in vacuo, the residue was dissolved in DCM (40 mL), washed with water (2 × 20 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue (4.3 g) was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, DCM, DCM/MeOH 100:1, 100:2, 100:4). After evaporation of solvents in vacuo **20a** (2.97 g, 83%) was obtained as a pale yellow oil. IR (film): 2932, 1731, 1487, 1328, 1153, 1037 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.92 (d, 4J = 1.7 Hz, 1H), 7.42 (m, 2H), 6.87 (s, 1H), 6.80 (s, 1H), 4.93 (s, 1H), 4.11 (q, 3J = 7.2 Hz, 2H), 3.38 (s, 3H), 2.50 (t, 3J = 7.1 Hz, 2H), 2.28 (t, 3J = 7.5 Hz, 2H), 1.76 (br s, 1H), 1.61 (~qn, 3J = 7.2 Hz, 2H), 1.50 (m, 2H), 1.32 (m, 4H), 1.24 (t, 3J = 7.1 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): 173.63, 147.88, 147.62, 140.73, 137.39, 134.44, 134.13, 131.87, 131.19, 129.90, 128.26, 108.54, 107.98, 101.96, 64.55, 60.11, 48.18, 38.13, 34.15, 29.85, 28.90, 26.88, 24.75, 14.18. MS (ESI): [M+H]⁺: 509 (1 Cl). HRMS (ESI): m/z calcd. for C₂₄H₃₀ClN₂O₆S [M+H]⁺: 509.1508, found: 509.1505.

7-[(8-Chloro-5-methyl-6,6-dioxido-5,11-dihydro[1,3]benzodioxolo[5,6-

c]benzo[f][1,2]thiazepin-11-yl)amino]heptanoic acid (20b). To a solution of ester 20a (2.55 g, 5 mmol) in EtOH (30 mL), a solution of NaOH (0.240 g, 6 mmol) in water (7.5 mL) was added at room temperature and it was stirred at room temperature for 25 h. Water (15 mL) was added and the ethanol was removed by evaporation in vacuo. Water (8 mL) was added, and the solution was neutralized with an aqueous HCl solution (0.50 mL of cc. HCl dissolved in 10 mL of water, containing 6 mmol of HCl). The milky reaction mixture was stirred at room temperature for 3 days, the solid product obtained was filtered, washed with water (2 × 3 mL), air-dried and subjected to dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:2, 100:4). After evaporation of solvents the solid residue was triturated with CH₃CN (5 mL) to afford 20b (1.92 g, 80%) as colorless crystals. M. p. 126–128 °C (CH₃CN). IR (KBr): 3081, 1712, 1493, 1326, 1224, 1034 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 7.75 (d, 4J = 1.8 Hz, 1H), 7.68 (dd, 4J = 2.2 Hz, 3J =

8.5 Hz, 1H), 7.65 (d, ${}^{3}J$ = 8.6 Hz, 1H), 7.15 (s, 1H), 7.04 (s, 1H), 6.08 (d, ${}^{4}J$ = 0.7 Hz, 1H), 6.06 (d, ${}^{4}J$ = 0.6 Hz, 1H), 5.11 (s, 1H), 3.37 (s, 3H), 2.44 (m, 2H), 2.18 (t, ${}^{3}J$ = 7.3 Hz, 2H), 1.47 (m, 4H), 1.26 (m, 4H). 13 C NMR (125 MHz, DMSO- d_6): 174.68, 147.41, 147.38, 141.30, 138.55, 135.93, 132.77, 131.96, 130.82, 126.86, 109.08, 107.38, 102.18, 61.99, 47.74, 37.83, 33.81, 29.47, 28.69, 26.73, 24.66. MS (ESI): [M+H]⁺: 481 (1 Cl). HRMS (ESI): m/z calcd. for $C_{22}H_{26}ClN_2O_6S$ [M+H]⁺: 481.1195, found: 481.1201.

8-Chloro-*N*,5-dimethyl-5,11-dihydro[1,3]benzodioxolo[5,6-c]benzo[f][1,2]thiazepin-11-amine 6,6-dioxide (20c). To the solution of methylamine (1.40 g, 45 mmol) in dioxane (45 mL) crude **18** (3.35 g, 9 mmol) was added, and the suspension obtained was stirred at room temperature for 1 h. Water (150 mL) was added dropwise, the product precipitated was filtered, washed with water (2 × 10 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1, 100:2, 100:4). After evaporation of solvents, the solid residue was triturated with CH₃CN (15 mL) to afford **20c** (1.86 g, 56%) as colorless crystals. M. p. decomp. from 218 °C (CH₃CN). IR (KBr): 1501, 1485, 1325, 1154, 1036 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (d, 4J = 2.1 Hz, 1H), 7.43 (dd, 4J = 2.0 Hz, 3J = 8.4 Hz, 1H), 6.87 (s, 1H), 6.81 (s, 1H), 5.98 (d, 4J = 1.1 Hz, 1H), 5.97 (d, 4J = 1.1 Hz, 1H), 4.82 (s, 1H), 3.37 (s, 3H), 2.38 (s, 3H), 1.86 (br s, 1H). ¹³C NMR (125 MHz, CDCl₃): 147.96, 147.64, 140.69, 136.96, 134.24, 133.82, 131.90, 131.34, 130.11, 128.35, 108.51, 108.23, 101.99, 66.52, 38.21, 34.98. MS (ESI): [M+H]⁺: 367 (1 Cl). HRMS (ESI): m/z calcd. for C₁₆H₁₆ClN₂O₄S [M+H]⁺: 367.0514, found: 367.0516.

8-Chloro-5-methyl-*N*-**(2-morpholin-4-ylethyl)-5,11-dihydro**[1,3]benzodioxolo[5,6-c]benzo[f][1,2]thiazepin-11-amine 6,6-dioxide (20d). To the solution of 4-(2-aminoethyl)morpholine (1.15 g, 8.8 mmol) in CH₃CN (15 mL) crude 18 (1.49 g, 4 mmol) was added, and the suspension obtained was stirred at room temperature for 1 h. Water (50 mL) was added dropwise, the product separated was filtered, washed with water (3 × 3 mL) air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:2). After evaporation of solvents, the solid residue was triturated with CH₃CN to afford 20d (1.58 g, 84%) as colorless crystals. M. p. 207–209 °C (CH₃CN, decomp.). IR (KBr): 3331, 1488, 1326, 1116, 1029 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (m, 1H), 7.42 (m, 2H), 6.89 (s, 1H), 6.81 (s, 1H), 5.98 (d, 4J = 1.3 Hz, 1H), 5.97 (d, 4J = 1.4 Hz, 1H), 4.93 (s, 1H), 3.67 (m, 4H), 3.42 (s, 3H), 2.63 (m, 2H), 2.50 (m, 2H), 2.37 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 147.96, 147.70, 140.84, 137.43, 134.77, 134.24, 131.82, 131.17, 129.80, 128.31, 108.51, 107.75, 102.00, 66.88 (2C), 64.38, 58.05, 53.68 (2C), 44.27,

37.97. MS (ESI): [M+H]⁺: 466 (1 Cl). HRMS (ESI): m/z calcd. for C₂₁H₂₅ClN₃O₅S [M+H]⁺: 466.1198, found: 466.1202.

8-Chloro-5-methyl-11-pyrrolidin-1-yl-5,11-dihydro[1,3]benzodioxolo[5,6-

c|benzo[*f*][1,2]thiazepine 6,6-dioxide (20e). To the cooled solution of pyrrolidine (0.71 g, 10 mmol, 0.83 mL) in CH₃CN (10 mL) crude **18** (1.49 g, 4 mmol) was added. The suspension formed was stirred at room temperature for 1 h. Water (40 mL) was added dropwise, the product separated was filtered, washed with water (3 × 3 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: heptane/DCM 2:1, 1:1, DCM, DCM/MeOH 100:1). After evaporation of solvents, the solid residue was triturated with CH₃CN (5 mL) to afford TLC pure **20e** (1.11 g, 68%) as colorless crystals. M. p. decomp. from 215 °C (CH₃CN). IR (KBr): 1483, 1316, 1226, 1033 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.92 (d, 4J = 2.2 Hz, 1H), 7.36 (dd, 4J = 2.2 Hz, 3J = 8.3 Hz, 1H), 7.30 (d, 3J = 8.3 Hz, 1H), 6.89 (s, 1H), 6.75 (s, 1H), 6.01 (d, 4J = 1.3 Hz, 1H), 5.95 (d, 4J = 1.5 Hz, 1H), 4.05 (br s, 1H), 3.46 (s, 3H), 2.27 (m, 2H), 2.18 (m, 2H), 1.70 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 148.20, 147.64, 142.76, 135.75, 135.52, 134.88, 132.60, 131.18, 131.07, 128.22, 110.64, 109.34, 102.06, 75.99, 53.71 (2C), 39.58, 23.19 (2C). MS (EI): [M]⁺: 406 (1 Cl). HRMS (ESI): m/z calcd. for C₁₉H₂₀ClN₂O₄S [M+H]⁺: 407.0827, found: 407.0831.

9-Chloro-N,6-dimethyl-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c|benzo[*f*][1,2]thiazepin-12-amine 7,7-dioxide (21c). To the cold solution of methylamine (0.745 g, 24 mmol) in dioxane (17 mL) crude 19 (1.85 g, 4.8 mmol) was added, and the suspension obtained was stirred at room temperature for 45 min. After evaporation in vacuo the solid residue was triturated with water (15 mL), filtered, air-dried and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1). After evaporation of solvents, the solid residue was triturated with DIPE (10 mL) to afford 21c (1.71 g, 93%) as colorless crystals. M. p. decomp. from 212 °C (CH₃CN). IR (KBr): 1508, 1324, 1064, 594 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.95 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.44 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.2 Hz, 1H), 7.39 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.92 (s, 1H), 6.85 (s, 1H), 4.73 (s, 1H), 4.24 (s, 4H), 3.33 (s, 3H), 2.34 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): 143.71, 143.29, 140.74, 136.68, 134.20, 132.02, 131.95, 131.28, 130.99, 128.45, 117.90, 116.92, 67.34, 64.32, 64.27, 38.75, 34.91. MS (EI): [M]⁺: 380 (1 Cl). HRMS (ESI): m/z calcd. for C₁₇H₁₈ClN₂O₄S [M+H]⁺: 381.0670, found: 381.0677.

9-Chloro-6-methyl-*N*-(2-morpholin-4-ylethyl)-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepin-12-amine 7,7-dioxide (21d). To the solution of 4-(2-aminoethyl)morpholine (1.15 g, 8.8 mmol) in CH₃CN (15 mL) crude 19 (1.55 g, 4 mmol) was

added. The solution obtained was stirred at room temperature for 1 h. Water (50 mL) was added dropwise in 30 min, the product separated was filtered, washed with water (2 × 5 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM, DCM/MeOH 100:2). After evaporation of solvents, the solid residue was triturated with CH₃CN (10 mL), filtered and recrystallized from CH₃CN (85 mL) to afford **21d** (1.46 g, 75%) as colorless crystals. M. p. decomp. from 217 °C (CH₃CN). IR (KBr): 1509, 1323, 1147, 1065 cm⁻¹. ¹H NMR (500 MHz, CDCl3): 7.94 (d, 4J = 2.1 Hz, 1H), 7.43 (dd, 4J = 2.1 Hz, 3J = 8.3 Hz, 1H), 7.39 (d, 3J = 8.3 Hz, 1H), 6.94 (s, 1H), 6.85 (s, 1H), 4.85 (s, 1H), 4.23 (s, 4H), 3.67 (m, 4H), 3.39 (s, 3H), 2.58 (m, 2H), 2.47 (m, 2H), 2.46 (br s, 1H), 2.35 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.65, 143.33, 140.95, 137.18, 134.12, 133.06, 131.82, 130.97, 130.54, 128.30, 117.20, 116.96, 66.85 (2C), 64.96, 64.29, 64.20, 58.04, 53.63 (2C), 44.17, 38.41. MS (EI): [M]⁺: 479 (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₇ClN₃O₅S [M+H]⁺: 480.1354, found: 480.1353.

ino[6,7-c]benzo[f][1,2]thiazepin-12-amine 7,7-dioxide (21e). To the solution of 4-(3-aminopropyl)morpholine (1.27 g, 8.8 mmol) in CH₃CN (15 mL) crude 19 (1.55 g, 4 mmol) was added. The solution obtained was stirred at room temperature for 1.5 h. Water (100 mL) was added dropwise, the oily product separated was extracted with DCM (2×25 mL), the combined organic phases were washed with water (20 mL), dried over Na₂SO₄, and partly evaporated in vacuo (to a volume of 20 mL). The solution obtained was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM, DCM/MeOH 100:2, 100:4). After evaporation of solvents, the oily residue was triturated with water (30 mL), filtered and recrystallized from CH₃CN to afford 21e (1.29 g, 65%) as bright colorless crystals. M. p. 164–166 °C (CH₃CN). IR (KBr): 1500, 1304, 1146, 1116, 1069 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (d, ⁴J = 0.7 Hz, 1H), 7.43 (m, 2H), 6.93 (s, 1H), 6.85 (s, 1H), 4.92 (s, 1H), 4.23 (s, 4H), 3.66 (m, 4H), 3.35 (s, 3H), 2.57 (m, 2H), 2.42 (m, 4H), 2.40 (t, ³J = 7.0 Hz, 2H), 2.35 (br s, 1H), 1.69 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): 143.55, 143.35, 140.68, 137.45, 134.00, 133.13, 131.87, 130.97, 130.04, 128.36, 116.97, 116.93, 66.89 (2C),

9-Chloro-6-methyl-N-(3-morpholin-4-ylpropyl)-2,3,6,12-tetrahydro[1,4]benzodiox-

9-Chloro-6-methyl-*N*-(4-morpholin-4-ylbutyl)-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-*c*]benzo[*f*][1,2]thiazepin-12-amine 7,7-dioxide (21f). To the solution of 4-(4-aminobutyl)morpholine (1.39 g, 8.8 mmol) in CH₃CN (15 mL) crude 19 (1.55 g, 4 mmol) was added. The solution obtained was stirred at room temperature for 1 h. Water (60 mL) was added

64.32, 64.30, 64.21, 57.31, 53.74 (2C), 46.90, 38.39, 26.37. MS (ESI): [M+H]⁺: 494 (1 Cl).

HRMS (ESI): m/z calcd. for C₂₃H₂₉ClN₃O₅S [M+H]⁺: 494.1511, found: 494.1513.

dropwise in 30 min, the oily product separated was extracted with DCM (3 × 25 mL), the combined organic phases were washed with water (25 mL), dried over Na₂SO₄, and evaporated in vacuo. The residue was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:2, 100:4). After evaporation of solvents, the foamy residue was dissolved in CH₃CN (20 mL), the opalescent solution was treated with charcoal, the clear solution obtained was evaporated in vacuo to afford **21f** (1.43 g, 70%) as colorless foam. IR (KBr): 3332, 2936, 1507, 1321, 1116, 1066 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (d, ⁴J = 2.0 Hz, 1H), 7.42 (dd, ⁴J = 2.1 Hz, ³J = 8.3 Hz, 1H), 7.39 (d, ³J = 8.3 Hz, 1H), 6.91 (s, 1H), 6.84 (s, 1H), 4.86 (s, 1H), 4.22 (s, 4H), 3.68 (m, 4H), 3.34 (s, 3H), 2.49 (~q, ³J = 3.8 Hz, 2H), 2.39 (m, 4H), 2.29 (t, ³J = 6.8 Hz, 2H), 1.94 (br s, 1H), 1.50 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.56, 143.21, 140.71, 137.06, 133.99, 132.52, 131.84, 131.04, 130.65, 128.27, 117.50, 116.88, 66.83 (2C), 65.14, 64.22, 64.15, 58.65, 53.61 (2C), 47.89, 38.62, 27.84, 24.18. MS (ESI): [M+H]⁺: 508 (1 Cl). HRMS (ESI): m/z calcd. for C₂₄H₃₁ClN₃O₅S [M+H]⁺: 508.1667, found: 508.1669.

9-Chloro-6-methyl-12-pyrrolidin-1-yl-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepine 7,7-dioxide (21g). To the cooled suspension of crude 19 (1.74 g, 4.5 mmol) in CH₃CN (15 mL) pyrrolidine (0.80 g, 11.3 mmol, 0.94 mL) was added in one portion. An exothermic reaction took place, a solution was formed, which was followed by rapid precipitation. The suspension obtained was stirred at room temperature for 1 h. Water (60 mL) was added dropwise, the product separated was filtered, washed with water (3 × 3 mL), and air-dried. It was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM). After evaporation of solvent, the solid residue triturated with Et₂O (5 mL) to give 21g (1.30 g, 69%) as colorless crystals. M. p. decomp. from 216 °C (CH₃CN). IR (KBr): 2933, 1586, 1506, 1320, 1138, 1067 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (d, 4J = 2.1 Hz, 1H), 7.36 (dd, 4J = 2.2 Hz, 3J = 8.3 Hz, 1H), 7.29 (d, 3J = 8.3 Hz, 1H), 6.97 (s, 1H), 6.79 (s, 1H), 4.23 (m, 4H), 4.03 (s, 1H), 3.47 (s, 3H), 2.25 (m, 2H), 2.17 (m, 2H), 1.68 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.84, 143.44, 143.09, 135.79, 134.80, 134.64, 132.72, 131.02, 130.65, 128.33, 119.37, 118.26, 75.64, 64.32, 64.17, 53.68 (2C), 39.93, 23.19 (2C). MS (EI): [M]⁺: 420 (1 Cl). HRMS (ESI): m/z calcd. for C₂₀H₂₂ClN₂O₄S [M+H]⁺: 421.0983, found: 421.0985.

9-Chloro-6-methyl-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepin-12-amine 7,7-dioxide (21h). To a cold, 1 m/m % ammonia solution in dioxane (204 g, containing 2.04 g, 120 mmol NH₃) crude **19** (4.63 g, 12 mmol) was added, the thin suspension was stirred at room temperature for 2 h, then evaporated in vacuo. The solid residue (7.1 g) was triturated

with water (20 mL), filtered, washed with water (2 × 10 mL), dried in vacuo and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1). After evaporation of solvents, the foamy residue was triturated with DIPE (20 mL), filtered, washed with DIPE (5 mL) to afford **21h** (2.10 g, 48%) as colorless crystals. M. p. decomp. from 200 °C (EtOH/CH₃CN). IR (KBr): 3368, 1503, 1322, 1143, 1062 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 7.79 (d, 3J = 8.5 Hz, 1H), 7.73 (d, 4J = 2.3 Hz, 1H), 7.69 (dd, 4J = 2.3 Hz, 3J = 8.6 Hz, 1H), 7.05 (s, 1H), 7.03 (s, 1H), 5.47 (s, 1H), 4.23 (s, 4H), 3.32 (s, 3H), 2.57 (br s, 2H). ¹³C NMR (125 MHz, DMSO- d_6): 143.41, 142.90, 140.85, 140.61, 137.22, 132.27, 132.11, 129.57, 129.34, 126.73, 116.56, 115.04, 64.32, 64.22, 53.17, 37.59. MS (EI): [M]⁺: 366 (1 Cl). HRMS (ESI): m/z calcd. for C₁₆H₁₆ClN₂O₄S [M+H]⁺: 367.0514, found: 367.0519.

7-[(9-Chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c|benzo[*f*][1,2]thiazepin-12-yl)amino]-*N*,*N*-dimethylheptanamide (21i). To a solution of 7-amino-*N*,*N*-dimethylheptanamide (1.45 g, 8.4 mmol) in CH₃CN (20 mL) crude **19** (1.545 g, 4 mmol) was added and the solution obtained was stirred at room temperature for 3.5 h. It was evaporated in vacuo, the residue was dissolved in DCM (50 mL), washed with water (3 × 20 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 40 mm, eluent: DCM, DCM/MeOH 100:1, 100:2). After evaporation of solvents in vacuo **21i** (1.47 g, 70%) was obtained as a colorless foam. IR (KBr): 3446, 2929, 1641, 1507, 1320, 1143, 1066 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.92 (d, ⁴*J* = 2.0 Hz, 1H), 7.43 (dd, ⁴*J* = 2.0 Hz, ³*J* = 8.2 Hz, 1H), 7.40 (d, ³*J* = 8.4 Hz, 1H), 6.91 (s, 1H), 6.83 (s, 1H), 4.85 (s, 1H), 4.23 (s, 4H), 3.35 (s, 3H), 2.98 (s, 3H), 2.93 (s, 3H), 2.47 (m, 2H), 2.28 (t, ³*J* = 7.5 Hz, 2H), 1.87 (br s, 1H), 1.61 (m, 2H), 1.48 (m, 2H), 1.32 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 172.92, 143.59, 143.27, 140.85, 137.20, 134.01, 132.77, 131.87, 131.08, 130.71, 128.27, 117.51, 116.98, 65.25, 64.26, 64.19, 48.06, 38.63, 37.16, 35.25, 33.13, 29.85, 29.23, 27.04, 24.94. MS (ESI): [M+H]⁺: 522 (1 CI). HRMS (ESI): m/z calcd. for C₂₅H₃₃ClN₃O₅S [M+H]⁺: 522.1824, found: 522.1829.

9-Chloro-6-methyl-*N***-(2-pyrrolidin-1-ylethyl)-2,3,6,12-tetrahydro**[1,4]benzodioxino[6,7-*c*]benzo[*f*][1,2]thiazepin-12-amine 7,7-dioxide (21j). To the solution of 4-(2-aminoethyl)pyrrolidine (1.01 g, 8.8 mmol) in CH₃CN (15 mL) crude **19** (1.55 g, 4 mmol) was added. The solution obtained was stirred at room temperature for 1 h. Water (60 mL) was added, the oily product separated was extracted with DCM (30 + 15 mL), the combined organic phases were washed with water (15 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column chromatography on a short silica gel column (thickness of

stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1, 100:2, 100:4). After evaporation of solvents, the solid residue was recrystallized from CH₃CN (50 mL) to afford **21j** (1.35 g, 72%) as colorless crystals. M. p. decomp. from 190 °C (CH₃CN). IR (KBr): 3281, 2788, 1509, 1325, 1159, 1061 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (br s, 1H), 7.41 (m, 2H), 6.94 (s, 1H), 6.85 (s, 1H), 4.86 (s, 1H), 4.22 (s, 4H), 3.40 (s, 3H), 2.59 (m, 4H), 2.41 (m, 4H), 2.35 (br s, 1H), 1.73 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.59, 143.31, 141.14, 137.29, 134.04, 133.32, 131.80, 130.89, 130.69, 128.14, 117.31, 117.03, 65.12, 64.27, 64.18, 55.56, 54.08 (2C), 46.73, 38.32, 23.39 (2C). MS (ESI): [M+H]⁺: 464 (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₇ClN₃O₄S [M+H]⁺: 464.1405, found: 464.1407.

9-Chloro-6-methyl-N-(2-piperidin-1-ylethyl)-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7c|benzo[f][1,2]thiazepin-12-amine 7,7-dioxide (21k). To the solution aminoethyl)piperidine (1.13 g, 8.8 mmol) in CH₃CN (15 mL) crude 19 (1.55 g, 4 mmol) was added. The thin suspension obtained was stirred at room temperature for 1 h. Water (60 mL) was added dropwise in 30 min, the oily product separated was extracted with DCM (30 + 15 mL), the combined organic phases were washed with water (15 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1, 100:2). After evaporation of solvents, the foamy residue was dissolved in CH₃CN (5 mL), crystallization occurred when cooling it at 5 °C for 3 days to afford **21k** (1.455 g, 76%) as colorless crystals. M. p. decomp. from 141 °C (CH₃CN). IR (KBr): 3302, 2937, 1508, 1323, 1148, 1065 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (m, 1H), 7.41 (m, 2H), 6.94 (s, 1H), 6.84 (s, 1H), 4.86 (d, ${}^{3}J$ = 3.8 Hz, 1H), 4.22 (s, 4H), 3.42 (s, 3H), 2.58 (\sim q, ${}^{3}J$ = 5.0 Hz, 2H), 2.41 (t, $^{3}J = 6.0 \text{ Hz}, 2\text{H}, 2.37 (\sim \text{bq}, ^{3}J = 5.5 \text{ Hz}, 1\text{H}), 2.28 (\text{br s}, 4\text{H}), 1.52 (\sim \text{qn}, ^{3}J = 5.6 \text{ Hz}, 4\text{H}), 1.40$ (m, 2H). ¹³C NMR (125 MHz, CDCl₃): 143.58, 143.37, 141.14, 137.38, 134.04, 133.54, 131.76, 130.88, 130.48, 128.20, 117.13, 117.08, 64.85, 64.28, 64.19, 58.34, 54.70 (2C), 44.86, 38.41, 25.95 (2C), 24.35. MS (ESI): [M+H]⁺: 478 (1 Cl). HRMS (ESI): m/z calcd. for C₂₃H₂₉ClN₃O₄S [M+H]⁺: 478.1562, found: 478.1564.

N'-(9-Chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepin-12-yl)-N,N-dimethylethane-1,2-diamine (211). To the solution of 2-(dimethylamino)ethylamine (0.88 g, 10 mmol) in CH₃CN (15 mL) crude 19 (1.70 g, 4.4 mmol) was added. The thick suspension obtained was stirred at room temperature for 1 h. Water (60 mL) was added dropwise, the separated product was filtered, washed with water (2 × 5 mL). The wet crude product was dissolved in DCM (35 mL), water was separated, the organic phase was dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by dry-column

chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:2, 100:4). After evaporation of solvents, the solid residue was crystallized from CH₃CN (30 mL) to afford **211** (1.54 g, 80%) as colorless crystals. M. p. decomp. from 190 °C (CH₃CN). IR (KBr): 2944, 1509, 1325, 1147, 1060 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.92 (br s, 1H), 7.42 (m, 2H), 6.94 (s, 1H), 6.85 (s, 1H), 4.88 (s, 1H), 4.22 (s, 4H), 3.41 (s, 3H), 2.56 (t, ${}^{3}J$ = 5.7 Hz, 2H), 2.39 (t, ${}^{3}J$ = 5.6 Hz, 2H), 2.31 (br s, 1H), 2.15 (s, 6H). ¹³C NMR (125 MHz, CDCl₃): 143.57, 143.32, 141.14, 137.34, 134.02, 133.46, 131.81, 130.84, 130.49, 128.12, 117.14, 117.08, 64.86, 64.26, 64.17, 58.80, 45.52, 45.41 (2C), 38.28. MS (ESI): [M+H]⁺: 438 (1 Cl). HRMS (ESI): m/z calcd. for C₂₀H₂₅ClN₃O₄S [M+H]⁺: 438.1249, found: 438.1253.

N'-(9-Chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c|benzo[f][1,2]thiazepin-12-yl)-N,N-dimethylpropane-1,3-diamine (21m). To the solution of 3-(dimethylamino)-1-propylamine (0.90 g, 8.8 mmol) in CH₃CN (15 mL) crude 19 (1.55 g, 4 mmol) was added. The solution obtained was stirred at room temperature for 1 h. Water (60 mL) was added dropwise, the oily product separated was extracted with DCM (30 + 15 mL), the combined organic phases were washed with water (15 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:2, 100:4). After evaporation of solvents, the foamy residue was dissolved in CH₃CN (5 mL), crystallization occurred when cooling it at 5 °C overnight to afford 21m (1.355 g, 75%) as colorless crystals. M. p. 154–156 °C (CH₃CN). IR (KBr): 3199, 1508, 1319, 1066 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.92 (br s, 1H), 7.42 (m, 2H), 6.92 (s, 1H), 6.84 (s, 1H), 4.90 (s, 1H), 4.22 (s, 4H), 3.36 (s, 3H), 2.56 (m, 2H), 2.30 (t, ${}^{3}J = 7.0 \text{ Hz}$, 2H), 2.22 (br s, 1H), 2.20 (s, 6H), 1.66 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): 143.52, 143.33, 140.76, 137.41, 133.94, 133.18, 131.86, 130.90, 130.22, 128.26, 117.08, 116.92, 64.53, 64.26, 64.17, 58.04, 46.86, 45.49 (2C), 38.36, 27.81. MS (ESI): [M+H]⁺: 452 (1 Cl). HRMS (ESI): m/z calcd. for C₂₁H₂₇ClN₃O₄S [M+H]⁺: 452.1405, found: 452.1406.

Ethyl 1-(9-chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepin-12-yl)piperidine-4-carboxylate (21n). To the solution of ethyl piperidine-4-carboxylate (1.04 g, 6.6 mmol) in CH₃CN (10 mL) crude 19 (1.16 g, 3 mmol) was added. The thick suspension obtained was diluted with CH₃CN (5 mL) and stirred at room temperature for 1 h. Water (70 mL) was added dropwise, the product separated was filtered, washed with water (2 × 5 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1,

100:2). After evaporation of solvents, the solid residue was recrystallized from CH₃CN to afford **21n** (1.175 g, 77%) as colorless crystals. M. p. 229–231 °C (CH₃CN). IR (KBr): 2949, 1730, 1508, 1318, 1141, 1068 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.94 (d, ⁴J = 2.2 Hz, 1H), 7.35 (dd, ⁴J = 2.3 Hz, ³J = 8.3 Hz, 1H), 7.22 (d, ³J = 8.3 Hz, 1H), 6.98 (s, 1H), 6.74 (s, 1H), 4.24 (m, 2H), 4.21 (m, 2H), 4.11 (q, ³J = 7.1 Hz, 2H), 3.95 (s, 1H), 3.49 (s, 3H), 2.64 (m, 1H), 2.47 (m, 1H), 2.26 (m, 1H), 1.88 (m, 2H), 1.81 (m, 2H), 1.64 (m, 2H), 1.23 (t, ³J = 7.1 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): 174.79, 144.00, 143.47, 143.16, 135.09, 134.41, 133.61, 133.47, 131.02, 130.29, 128.73, 119.65, 119.00, 76.70, 64.29, 64.15, 60.35, 52.23, 52.01, 40.73, 40.41, 28.35, 27.94, 14.15. MS (ESI): [M+H]⁺: 507 (1 Cl). HRMS (ESI): m/z calcd. for C₂₄H₂₈ClN₂O₆S [M+H]⁺: 507.1351, found: 507.1350.

1-(9-Chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c|benzo[f][1,2]thiazepin-12-yl)piperidine-4-carboxamide (210). To the solution of piperidine-4-carboxamide (isonipecotamide, 1.41 g, 11 mmol) in CH₃CN (175 mL) crude 19 (1.93 g, 5 mmol) was added and the suspension obtained was stirred at room temperature for 1.5 h. Water (350 mL) was added dropwise in 30 min, the product separated was filtered, washed with water (2 × 15 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:3). After evaporation of solvents, the TLC pure solid residue was triturated with CH₃CN (15 mL) to afford **210** (2.02 g, 84%) as colorless crystals. M. p. 272–275 °C (CH₃CN, decomp.) IR (KBr): 3437, 3159, 2944, 1685, 1506, 1319, 1065 cm⁻¹. ¹H NMR (500 MHz, DMSO-*d*₆): 7.77 (d, ${}^{4}J$ = 2.3 Hz, 1H), 7.64 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 7.53 (d, ${}^{3}J$ = 8.6 Hz, 1H), 7.21 (br s, 1H), 7.03 (s, 1H), 6.96 (s, 1H), 6.73 (br s, 1H), 4.25 (m, 4H), 4.24 (s, 1H), 3.43 (s, 3H), 2.54 (m, 1H), 2.31 (m, 1H), 2.04 (m, 1H), 1.83 (m, 2H), 1.61 (m, 2H), 1.44 (m, 2H). ¹³C NMR (125 MHz, DMSO-d₆): 176.54, 143.76, 143.39, 143.37, 135.12, 134.99, 133.86, 133.66, 131.43, 129.97, 127.42, 119.42, 119.16, 74.61, 64.29, 64.23, 52.08, 51.78, 41.58, 40.28, 28.80, 28.33. MS (ESI): [M+H]⁺: 478 (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₅ClN₃O₅S [M+H]⁺: 478.1198, found: 478.1199.

1-(9-Chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepin-12-yl)piperidine-4-carbonitrile (21p). To the solution of piperidine-4-carbonitrile (4-cyanopiperidine) (0.99 g, 9.0 mmol) in CH₃CN (15 mL) crude 19 (1.55 g, 4 mmol) was added. The suspension obtained was stirred at room temperature for 2.5 h. Water (70 mL) was added dropwise, the product separated was filtered, washed with water (2 × 5 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM, DCM/MeOH 100:1, 100:2). After

evaporation of solvents, the residue was triturated with CH₃CN, filtered and dried in vacuo (0.1 mm Hg, at 90 °C for 24 h) to afford **21p** (1.60 g, 87%) as colorless crystals. M. p. 229–232 °C (CH₃CN, decomp.). IR (KBr): 2928, 2240, 1508, 1320, 1143, 1067 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.94 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.37 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 7.24 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.98 (s, 1H), 6.75 (s, 1H), 4.22 (m, 4H), 4.01 (s, 1H), 3.46 (s, 3H), 2.65 (m, 1H), 2.47 (m, 1H), 2.37 (m, 1H), 2.24 (m, 1H), 2.13 (m, 1H), 1.80 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 144.15, 143.54, 143.08, 135.29, 133.81, 133.51, 132.87, 131.17, 130.13, 128.73, 121.29, 119.51, 119.06, 76.34, 64.25, 64.12, 50.30 (br), 40.10, 28.61, 25.81. MS (ESI): [M+H]⁺: 460 (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₃ClN₃O₄S [M+H]⁺: 460.1092, found: 460.1096.

9-Chloro-12-methoxy-6-methyl-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepine 7,7-dioxide (23a). The suspension of crude 19 (1.74 g, 4.5 mmol) in MeOH (15 mL) was stirred at room temperature for 2 h, while it was transformed to the suspension of the product. It was filtered, washed with MeOH (2 × 2 mL) and subjected to dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: heptane/DCM 1:1, DCM). After evaporation of solvents, the solid residue was triturated with MeOH to afford 23a (1.45 g, 84%) as colorless crystals. M. p. 218–220 °C (CH₃CN). IR (KBr): 1507, 1322, 1068, 596 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.91 (d, ${}^{4}J$ = 2.1 Hz, 1H), 7.58 (d, ${}^{3}J$ = 8.4 Hz, 1H), 7.44 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.5 Hz, 1H), 6.99 (s, 1H), 6.91 (s, 1H), 5.49 (s, 1H), 4.23 (m, 4H), 3.46 (s, 3H), 3.40 (m, 3H). ¹³C NMR (125 MHz, CDCl₃): 143.93, 143.73, 140.42, 135.84, 134.57, 132.88, 131.87, 129.87, 128.53, 128.00, 117.53, 115.36, 80.51, 64.31, 64.19, 57.85, 38.00. MS (EI): M^+ = 381 (1 Cl). HRMS (ESI): m/z calcd. for $C_{17}H_{16}CINNaO_{5}S$ [M+Na]⁺: 404.0330, found: 404.0331.

2-[(9-Chloro-6-methyl-7,7-dioxido-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepin-12-yl)oxy]-N,N-dimethylethanamine (23b). To the solution of 2-(dimethylamino)ethanol (0.89 g, 10 mmol) in CH₃CN (15 mL) crude 19 (1.70 g, 4.4 mmol) was added, and the solution obtained was stirred at room temperature for 3 h. Water (60 mL) was added dropwise, the precipitate was collected by filtration, washed with water (2 × 3 mL), airdried and purified by dry-column chromatography on a short aluminum oxide column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1, 100:2). After evaporation of solvents, the solid residue was recrystallized from CH₃CN (14 mL) to afford 23b (1.14 g, 59%) as colorless crystals. M. p. 175–178 °C (decomp.). IR (KBr): 1508, 1323, 1147, 1060 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.89 (d, 4J = 2.2 Hz, 1H), 7.63 (d, 3J = 8.4 Hz, 1H), 7.43 (dd, 4J = 2.2 Hz, 3J = 8.4 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 1H), 4.23 (m, 4H), 3.68 (m, 1H), 3.62 (m, 1H), 3.41 (s, 3H), 2.61 (m, 2H), 2.28 (s, 6H). ¹³C NMR

(125 MHz, CDCl₃): 143.83, 143.73, 140.29, 136.22, 134.41, 133.37, 131.87, 129.69, 128.33, 127.94, 117.33, 115.15, 78.67, 68.60, 64.29, 64.18, 58.93, 46.02 (2 Me), 37.86. MS (ESI): $[M+H]^+ = 439$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{20}H_{24}CIN_2O_5S$ $[M+H]^+$: 439.1089, found: 439.1091.

9-Chloro-6-methyl-12-(2-pyrrolidin-1-ylethoxy)-2,3,6,12-tetrahydro[1,4]benzodiox-

ino[6,7-c]benzo[f][1,2]thiazepine 7,7-dioxide(23c).solution of 1-(2-To the hydroxyethyl)pyrrolidine (2.30 g, 20 mmol) in CH₃CN (30 mL) crude **19** (3.40 g, 8.8 mmol) was added, and the solution obtained was stirred at room temperature for 2.5 h. Water (120 mL) was added dropwise, the oily product separated was extracted with DCM (2 × 50 mL). The combined organic phases were washed with water (50 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1, 100:2, 100:4). After evaporation of solvents, the solid residue was triturated with EtOH to afford 23c (1.56 g, 38%). M. p. 145-146 °C (CH₃CN, colorless crystals). IR (KBr): 2946, 1509, 1325, 1160, 1060 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.89 (d, $^{4}J = 2.2 \text{ Hz}$, 1H), 7.64 (d, $^{3}J = 8.5 \text{ Hz}$, 1H), 7.43 (dd, $^{4}J = 2.2 \text{ Hz}$, $^{3}J = 8.4 \text{ Hz}$, 1H), 6.97 (s, 1H), 6.95 (s, 1H), 4.22 (s, 4H), 3.71 (m, 1H), 3.65 (m, 1H), 3.40 (s, 3H), 2.79 (t, ${}^{3}J$ = 6.2 Hz, 2H), 2.55 (m, 4H), 1.77 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.81, 143.70, 140.29, 136.23, 134.38, 133.33, 131.84, 129.69, 128.39, 127.91, 117.30, 115.22, 78.70, 69.53, 64.27, 64.17, 55.51, 54.72 (2C), 37.89, 23.47 (2C). MS (ESI): $[M+H]^+ = 465$ (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₆ClN₂O₅S [M+H]⁺: 465.1245, found: 465.1249.

9-Chloro-6-methyl-12-(2-piperidin-1-ylethoxy)-2,3,6,12-tetrahydro[1,4]benzodiox-

ino[6,7-c]benzo[f][1,2]thiazepine 7,7-dioxide (23d). To the solution of 1-(2-hydroxyethyl)piperidine (1.29 g, 10 mmol) in CH₃CN (15 mL) crude 19 (1.70 g, 4.4 mmol) was added, and the solution obtained was stirred at room temperature for 2 h. Water (60 mL) was added dropwise, the oily product separated was extracted with DCM (2 × 30 mL). The combined organic phases were washed with water (30 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column chromatography on a short aluminum oxide column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 2:1, 1:1, DCM, DCM/MeOH 100:1). After evaporation of solvents the residue was triturated with CH₃CN to afford 23d (1.40 g, 66%) as colorless crystals. M. p. 133–135 °C (CH₃CN). IR (KBr): 1494, 1319, 1144, 1066 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.89 (d, 4J = 2.2 Hz, 1H), 7.66 (d, 3J = 8.6 Hz, 1H), 7.43 (dd, 4J = 2.1 Hz, 3J = 8.4 Hz, 1H), 6.97 (s, 1H), 6.96 (s, 1H), 5.69 (s, 1H), 4.22 (s, 4H), 3.69 (m, 1H), 3.64 (m, 1H), 3.40 (s, 3H), 2.63 (m, 2H), 2.42 (m, 4H), 1.57 (m,

4H), 1.43 (m, 2H). 13 C NMR (125 MHz, CDCl₃): 143.79, 143.67, 140.29, 136.25, 134.35, 133.28, 131.82, 129.74, 128.53, 127.86, 117.27, 115.29, 78.70, 68.17, 64.26, 64.16, 58.52, 55.08 (2C), 37.97, 25.95 (2C), 24.16. MS (ESI): [M+H]⁺ = 479 (1 Cl). HRMS (ESI): m/z calcd. for $C_{23}H_{28}CIN_2O_5S$ [M+H]⁺: 479.1402, found: 479.1403.

9-Chloro-6-methyl-12-(2-morpholin-4-ylethoxy)-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepine 7,7-dioxide (23e).To the solution of 4-(2hydroxyethyl)morpholine (1.15 g, 8.8 mmol) in CH₃CN (15 mL) crude **19** (1.55 g, 4 mmol) was added and the solution obtained was stirred at room temperature for 2 h. Water (60 mL) was added dropwise, the product separated was filtered, washed with water (2 × 3 mL), airdried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1, 100:2). After evaporation of solvents the residue was triturated with CH₃CN to afford 23e (1.61 g, 84%) as colorless crystals. M. p. 191-194 °C (CH₃CN, decomp.). IR (KBr): 1510, 1325, 1146, 1066 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.89 (d, ${}^{4}J$ = 2.1 Hz, 1H), 7.65 (d, ${}^{3}J$ = 8.4 Hz, 1H), 7.44 $(dd, {}^{4}J = 2.0 \text{ Hz}, {}^{3}J = 8.4 \text{ Hz}, 1\text{H}), 6.98 (s, 1\text{H}), 6.97 (s, 1\text{H}), 5.70 (s, 1\text{H}), 4.22 (s, 4\text{H}), 3.71$ (m, 1H), 3.70 (m, 4H), 3.65 (m, 1H), 3.40 (s, 3H), 2.68 (t, ${}^{3}J = 5.7$ Hz, 2H), 2.50 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.82, 143.66, 140.18, 136.15, 134.39, 133.05, 131.85, 129.73, 128.25, 127.90, 117.19, 115.11, 78.55, 67.74, 66.86 (2C), 64.25, 64.15, 58.18, 54.06 (2C), 37.91. MS (ESI): $[M+H]^+ = 481$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{22}H_{26}ClN_2O_6S$ $[M+H]^+$: 481.1195, found: 481.1200.

9-Chloro-6-methyl-12-[(2-morpholin-4-ylethyl)sulfanyl]-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepine 7,7-dioxide (24). To the solution of 2-(morpholin-4-yl)ethanethiol (1.30 g, 8.8 mmol) in CH₃CN (15 mL) crude **19** (1.55 g, 4 mmol) was added and it was stirred at room temperature for 1 h. Water (60 mL) was added dropwise, the product separated was filtered, washed with water (2 × 3 mL), and air-dried to give crude **24**. It was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM, DCM/MeOH 100:2). After evaporation of solvents, the solid residue was triturated with CH₃CN (10 mL) and filtered to afford crude **24** (1.93 g), which was recrystallized from CH₃CN to give **24** (1.44 g, 72%) as colorless crystals. M. p. decomp. from 240 °C (CH₃CN). IR (KBr): 1511, 1326, 1301, 1114, 1063 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.94 (d, ${}^{3}J$ = 8.2 Hz, 1H), 7.40 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 7.31 (d, ${}^{3}J$ = 8.3 Hz, 1H), 6.99 (s, 1H), 6.75 (s, 1H), 4.95 (s, 1H), 4.25 (m, 4H), 3.69 (m, 4H), 3.51 (s, 3H), 2.60 (m, 1H), 2.50 (m, 2H), 2.46 (m, 1H), 2.40 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 144.32, 143.05, 142.31, 134.63, 134.55, 132.50, 131.89, 131.72, 131.44, 127.79, 118.10, 117.90, 66.82 (2C), 64.33,

64.26, 58.22, 54.34, 53.54 (2C), 39.35, 30.28. MS (ESI): $[M+H]^+ = 497$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{22}H_{26}ClN_2O_5S_2$ $[M+H]^+$: 497.0966, found: 497.0970.

9-Chloro-2,3-dihydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepin-12(6H)-one 7,7-

dioxide (28). Compound 7 (14.89 g, 40.7 mmol) was mixed with pyridine hydrochloride (47 g, 407 mol) and the mixture was melted. The melt was stirred at 180 °C for 27 h. Water (230 mL) was added to the cooled reaction mixture (dark brown melt), the suspension obtained was stirred for 2 h, the product was filtered and washed thoroughly with water. The wet crude product on the sintered glass filter was treated with aqueous NaOH solution (80 + 30 mL, 116 g of 5 m/m % solution, containing 5.8 g, ca. 145 mmol NaOH). The filtrate was acidified with AcOH (10 mL, 173 mmol), the product precipitated was collected by filtration, washed with water (3 × 30 mL), air-dried and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 35 mm, eluent: CHCl₃, CHCl₃/MeOH 100:3) After evaporation of the solvents the solid residue was triturated with CH₃CN (40 mL) to afford 28 (6.27 g, 51%) as yellow solid. M. p. 276–278 °C (CH₃CN, bright yellow crystals). IR (KBr): 3146, 1600, 1503, 1289 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 11.72 (br s, 1H), 7.90 (dd, 4J = 2.1 Hz, ${}^{3}J = 8.2$ Hz, 1H), 7.88 (dd, ${}^{4}J = 0.4$ Hz, ${}^{4}J = 2.1$ Hz, 1H), 7.83 (dd, ${}^{4}J = 0.5$ Hz, ${}^{3}J =$ 8.2 Hz, 1H), 7.51 (s, 1H), 6.70 (s, 1H), 4.36 (m, 2H), 4.29 (m, 2H). ¹³C NMR (125 MHz, DMSO-*d*₆): 189.20, 149.53, 140.53, 139.65, 137.14, 134.46, 133.51, 132.97, 132.40, 122.01, 120.37, 118.36, 108.75, 65.18, 64.07. MS (EI): $M^+ = 351$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{15}H_{11}CINO_5S$ [M+H]⁺: 352.0041, found: 352.0046.

6-(2-Bromoethyl)-9-chloro-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[*f*][1,2]thiazepin-12-ol 7,7-dioxide (30). To the suspension of 29 (9.175 g, 20 mmol) in a mixture of THF (20 mL) and EtOH (20 mL), NaBH₄ (0.91 g, 24 mmol) was added in portions and the stirring was continued at room temperature for 30 min. Water (200 mL) was added, and the oily product separated was extracted with DCM (2 × 100 mL). The combined organic phases were washed with water (50 mL), dried over Na₂SO₄, and evaporated in vacuo to give crude 30 (9.09 g, 99%) as colorless foam suitable for next reaction step. IR (KBr): 3484, 1499, 1327, 1304, 1141, 1065 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 7.89 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.65 (d, ${}^{3}J$ = 8.4 Hz, 1H), 7.49 (dd, ${}^{4}J$ = 2.1 Hz, ${}^{3}J$ = 8.4 Hz, 1H), 7.04 (s, 1H), 6.94 (s, 1H), 6.07 (d, ${}^{3}J$ = 6.1 Hz, 1H), 4.25 (s, 4H), 4.03 (m, 2H), 3.54 (m, 1H), 3.47 (m, 1H), 3.38 (d, ${}^{3}J$ = 6.4 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃): 143.99, 143.97, 139.94, 136.91, 134.70, 133.42, 132.65, 129.22, 128.05, 127.92, 117.26, 116.74, 72.29, 64.31, 64.26, 52.83, 29.10. COSY: 7.89–7.49–7.65, 6.07–3.38, 4.03–(3.54, 3.47). HSQC (140 Hz): 7.89–127.92, 7.65–129.22, 7.49–132.65, 7.04–116.74, 6.94–117.26, 6.07–72.29, 4.25–64.31, 4.25–64.26, 4.03–52.83,

3.54-29.10, 3.47-29.10. HMBC (8 Hz, 140 Hz): 7.89-(136.91, 134.70, 132.65), 7.65-(139.94, 134.70, 72.29), 7.49-(136.91, 134.70, 127.92), 7.04-(143.97, 128.05, 72.29), 6.94-(143.99, 133.42), 6.07-(139.94, 136.91, 133.42, 129.22, 128.05, 116.74), 4.25-(143.99, 64.26), 4.25-(143.97, 64.31), 4.03-(128.05, 29.10), (3.54, 3.47)-52.83, 3.38-(136.91, 133.42, 72.29). MS (EI): $M^+=459$ (1 Br, 1 CI). HRMS (ESI): m/z calcd. for $C_{17}H_{15}BrClNNaO_5S$ [M+Na] $^+$: 481.9435, found: 481.9438.

6-(2-Bromoethyl)-9,12-dichloro-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[*f*][1,2]thiazepine 7,7-dioxide (31). To a vigorously stirred yellow solution of 30 (8.75 g, 19 mmol) in DCM (100 mL), SOCl₂ (4.52 g, 38 mmol, 2.76 mL) was added dropwise at room temperature and stirring was continued for 2.5 h. To the solution hexane (400 mL) was added dropwise, the product precipitated was filtered, washed with hexane (2 × 20 mL), and dried in vacuo to give 31 (6.02 g, 66%) as beige crystals. M. p. decomp. from 144 °C. The mother liquor of this product was evaporated in vacuo, the solid residue was triturated with a little cold Et₂O to give a second crop of crude 31 (2.21 g, 24%) as beige crystals. Total yield: 8.23 g, 90%. IR (KBr): 1510, 1332, 1303, 1160, 1064 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): 7.96 (d, 4J = 2.1 Hz, 1H), 7.48 (dd, 4J = 2.1 Hz, 3J = 8.4 Hz, 1H), 7.44 (d, 3J = 8.4 Hz, 1H), 7.10 (s, 1H), 6.92 (s, 1H), 6.04 (s, 1H), 4.33 (m, 1H), 4.26 (m, 4H), 4.01 (m, 1H), 3.73 (t, 3J = 7.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): 145.25, 143.97, 141.40, 136.19, 133.33, 132.89, 132.60, 130.58, 130.34, 128.20, 119.97, 118.87, 64.31, 64.29, 63.08, 54.27, 29.60. HRMS (TOF MS EI): m/z calcd. for [C₁₇H₁₄BrCl₂NO₄S]⁺: 476.9204, found: 476.9200.

S-[2-(9-Chloro-12-hydroxy-7,7-dioxido-2,3-dihydro[1,4]benzodioxino[6,7-

c]benzo[f][1,2]thiazepin-6(12H)-yl)ethyl] ethanethioate (32). To a solution of 30 (1.015 g, 2.2 mmol) in CH₃CN (10 mL), potassium thioacetate (0.43 g, 3.75 mmol, 1.7 equiv) and tetrabutylammonium bromide (0.032 g, 0.1 mmol, 4.5 mol%) were added, and the thin suspension was vigorously stirred at room temperature for 4 h. To the thin suspension obtained, water (50 mL) and EtOAc (25 mL) were added with stirring (25 min). The phases were separated, the aqueous phase was washed with EtOAc (10 mL), the combined organic phases were washed with water (15 mL), dried over Na₂SO₄, and evaporated in vacuo. The residue was subjected to dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1, 100:2). After evaporation of the solvents, the residue was dried in vacuo to afford 32 (0.84 g, 84%) as colorless foam. IR (KBr): 3479, 1692, 1500, 1306, 1155, 1139, 1064 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 7.92 (d, 4J = 1.9 Hz, 1H), 7.64 (d, 3J = 8.3 Hz, 1H), 7.51 (dd, 4J = 1.9 Hz, 3J = 8.3 Hz, 1H), 7.05 (s, 1H), 6.98 (s, 1H), 5.96 (d, 3J = 7.3 Hz, 1H), 4.26 (s, 4H), 3.77 (t, 3J = 7.3 Hz, 2H).

3.54 (d, ${}^{3}J$ = 7.3 Hz, 1H), 3.03 (m, 2H), 2.30 (s, 3H). ${}^{13}C$ NMR (150 MHz, CDCl₃): 195.08, 144.10, 143.67, 140.01, 136.61, 134.70, 132.70, 132.08, 129.76, 128.68, 127.94, 117.39, 116.81, 73.23, 64.32 (2C), 50.75, 30.58, 28.07. COSY: 7.64–7.51, 5.96–3.54, 3.77–3.03. HSQC (140 Hz): 7.92–127.94, 7.64–129.76, 7.51–132.70, 7.05–117.39, 6.98–116.81, 5.96–73.23, 4.26–64.32, 3.77–50.75, 3.03–28.07, 2.30–30.58. HMBC (140 Hz, 8 Hz): 7.92–(136.61, 134.70, 132.70), 7.64–(140.01, 134.70, 73.23), 7.51–(136.61, 127.94), 7.05–(144.10, 128.68, 73.23), 6.98–(143.67, 132.08), 5.96–(140.01, 136.61, 132.08, 129.76, 128.68, 117.39), 4.26–(143.67, 140.01, 64.32), 3.77–(128.68, 28.07), 3.54–(136.61, 132.08, 73.23), 3.03–(195.08, 50.75), 2.30–195.08. HRMS (ESI): m/z calcd. for $C_{19}H_{18}CINNaO_6S_2$ [M+Na]⁺: 478.0156, found: 478.0158.

9-Chloro-2,3-dihydro-12H-12,6-(epithioethano)[1,4]benzodioxino[6,7-

c|benzo[f][1,2]thiazepine 7,7-dioxide (26). To the solution of compound 32 (0.64 g, 1.4 mmol) in MeOH (12 mL), K₂CO₃ (0.31 g, 2.24 mmol) was added, and the reaction mixture was stirred under argon atmosphere at room temperature for 30 min. The solution obtained was diluted with water (30 mL), and aqueous HCl solution (5 m/m%, 4.2 mL) was added dropwise. The thiol intermediate separated was dissolved by adding DCM (40 mL), the layers were separated, and the aqueous layer was washed with DCM (10 mL). The combined organic phases were washed with water (15 mL), dried over Na₂SO₄ and evaporated in vacuo to give crude thiol intermediate as a dense colorless oil. It was dissolved in DCM (100 mL), p-TsOH·H₂O (0.057 g, 0.3 mmol, 21 mol %) was added and the reaction mixture was stirred under argon atmosphere at room temperature for 1 h. Then it was evaporated to 30 mL of volume and purified by passing it through a short silica gel column (thickness of stationary phase: 30 mm, eluent: DCM). After evaporation of the solvent, the partly crystalline residue was triturated with DIPE (5 mL) to afford **26** (0.504 g, 91%) as colorless crystals. M. p. 258–259.5 °C (CH₃CN). IR (KBr): 3449, 1506, 1338, 1304, 1159, 1062, 595 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 7.90 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.46 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.4 Hz, 1H), 7.32 (d, ${}^{3}J$ = 8.4 Hz, 1H), 6.99 (s, 1H), 6.78 (s, 1H), 4.78 (s, 1H), 4.47 (dt, ${}^{3}J$ = 14.6 Hz, ${}^{3}J$ = 3.0 Hz, 1H), 4.24 (m, 4H), 3.50 (~t, $^{3}J = 14.6 \text{ Hz}, 1\text{H}, 3.29 (~t, ^{3}J = 15.3 \text{ Hz}, 1\text{H}), 2.59 (dt, ^{3}J = 15.3 \text{ Hz}, ^{4}J = 2.9 \text{ Hz}, 1\text{H}).$ ¹³C NMR (150 MHz, CDCl₃): 143.93, 143.65, 143.57, 137.04, 134.65, 133.07, 132.81, 132.15, 131.20, 127.24, 120.19, 116.13, 64.34, 64.15, 51.70, 51.52, 27.79. COSY: 7.46–7.32, (4.47, 3.50)–(3.29, 2.59). HSQC (140 Hz): 7.90–127.24, 7.46–132.81, 7.32–132.15, 6.99–120.19, 6.78–116.13, 4.78–51.52, (4.47, 3.50)–51.70, 4.24–64.34/64.15, (3.29, 2.59)–27.79. HMBC (140 Hz, 8 Hz): 7.90–(134.65, 132.81), 7.46–(134.65, 127.24), 7.32–(143.65, 133.07, 51.52), 6.99–(143.93, 137.04, 132.10), 6.78–(143.57, 131.20, 51.52), 4.78–(143.65, 137.04, 131.20, 116.13, 27.79), (4.47, 3.50)–(131.20, 27.79), 4.24–(143.93, 143.57), (3.29, 2.59)–(51.70, 51.52). HRMS (ESI): m/z calcd. for $C_{17}H_{15}CINO_4S_2$ [M+H]⁺: 396.0126, found: 396.0128.

9-Chloro-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepin-12-ol 7,7-

dioxide (33). To a solution of **28** (9.74 g, 27.7 mmol) in an aqueous NaOH solution (5.54 g, 138.5 mmol NaOH dissolved in 250 mL of water), NaBH₄ (5.24 g, 138.5 mmol) was added in several portions while cooling the reaction mixture with tap water. After stirring at room temperature for 69 h (weekend), the yellow solution was cooled with ice-water, and an aqueous HCl solution (6 M, 60 mL) was added dropwise over a period of 30 min. The oily product separated was dissolved by adding DCM (300 mL), the phases were separated, the organic phase was dried over Na₂SO₄ and purified by passing through a short silica gel column (thickness of stationary phase: 35 mm, eluent: DCM, DCM/MeOH 100:1). After evaporation of the solvents, the residue (10.9 g of greyish foam) was triturated with CH₃CN to afford **33** (8.18 g, 83%) as pale pink crystals. M. p. decomp. from 180 °C. IR (KBr): 3488, 3238, 1509, 1322, 1138, 1066 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_0): 10.37 (br s, 1H), 7.87 (m, 1H), 7.71 (m, 2H), 7.10 (s, 1H), 6.70 (s, 1H), 6.66 (br s, 1H), 6.49 (s, 1H), 4.21 (m, 4H). ¹³C NMR (125 MHz, DMSO- d_0): 142.72, 142.26, 139.71, 139.41, 132.61, 132.42, 132.07, 127.44, 125.58, 125.27, 115.06, 113.64, 65.80, 64.32, 64.31. MS (ESI): [M-H]⁻ = 352 (1 Cl). HRMS (ESI): m/z calcd. for C₁₅H₁₂CINNaO₅S [M+Na]⁺: 376.0017, found: 376.0020.

9,12-Dichloro-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-c]benzo[f][1,2]thiazepine 7,7-

dioxide (34). To a vigorously stirred suspension of **33** (2.12 g, 6 mmol) in DCM (15 mL), SOCl₂ (0.95 g, 8 mmol, 0.58 mL) was added at room temperature. After 5 min of stirring the starting material was completely dissolved, and the product began to crystallize. Stirring was continued for 2 h, hexane (80 mL) was added dropwise to the suspension. The product was filtered, washed with hexane, and dried in vacuo to give crude **34** (2.23 g, 100%) as beige crystals. M. p. decomp. from 105 °C. IR (KBr): 3263, 1512, 1328, 1161, 1061 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.91 (d, 4J = 2.2 Hz, 1H), 7.46 (dd, 4J = 2.2 Hz, 3J = 8.3 Hz, 1H), 7.36 (d, 3J = 8.4 Hz, 1H), 7.23 (br s, 1H), 7.08 (s, 1H), 6.88 (s, 1H), 5.86 (s, 1H), 4.25 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 145.13, 143.80, 141.92, 136.82, 133.38, 132.49, 131.79, 130.76, 129.06, 126.21, 121.30, 117.65, 64.30, 64.24, 63.27. MS (ESI): [M-Cl+OH-H]⁻ = 352 (1 Cl) (after a rapid hydrolysis of **34** the compound **33** was detected).

12-(2-Bromoethoxy)-9-chloro-2,3,6,12-tetrahydro[1,4]benzodioxino[6,7-

c]benzo[*f*][1,2]thiazepine 7,7-dioxide (35). To a stirred solution of 2-bromoethanol (4.50 g, 36 mmol, 2.56 mL) in CH₃CN (15 mL), 34 (2.23 g, 6 mmol) was added in portions at 20 °C. The thin suspension obtained was stirred at room temperature for 6 h, then it was evaporated in

vacuo. The oily residue was purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, 1:2, DCM). After evaporation of the solvents the residue was triturated with Et₂O (5 mL), filtered and dried in vacuo to give **35** (1.69 g, 61%) as off-white crystals. M. p. decomp. from 180 °C. IR (KBr): 3210, 1498, 1320, 1158, 1064 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.89 (d, J^4J = 2.2 Hz, 1H), 7.67 (br s, 1H), 7.43 (dd, J_I = 2.2 Hz, J_I = 8.3 Hz, 1H), 7.37 (d, J_I = 8.3 Hz, 1H), 7.01 (s, 1H), 6.83 (s, 1H), 5.29 (br s, 1H), 4.22 (m, 4H), 3.84 (m, 1H), 3.79 (m, 1H), 3.50 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): 144.24, 143.55, 142.13, 136.24, 133.77, 132.02, 131.12, 130.59, 129.03, 125.84, 120.05, 116.90, 83.67, 69.27, 64.31, 64.19, 30.51. MS (ESI): [M-H]⁻ = 458 (1 Br, 1 Cl). HRMS (ESI): m/z calcd. for C₁₇H₁₅BrClNNaO₅S [M+Na]⁺: 481.9435, found: 481.9431.

9-Chloro-2,3-dihydro-12H-12,6-(epoxyethano)[1,4]benzodioxino[6,7-

c|benzo[f][1,2]thiazepine 7,7-dioxide (27). To a solution of 35 (1.475 g, 3.2 mmol) in CH₃CN (40 mL), K₂CO₃ (1.38 g, 10 mmol) was added, and the suspension obtained was stirred at room temperature for 5 h. Water (200 mL) was added dropwise. The product precipitated was filtered, washed with water (2 × 5 mL), air-dried and purified by dry-column flash chromatography on a short aluminum oxide column (thickness of stationary phase: 30 mm, eluent: hexane/DCM 1:1, 1:2, DCM). After evaporation of the solvents the residue was recrystallized from CH₃CN (12 mL) to afford **27** (0.86 g, 71%) as colorless crystals. M. p. 228–229 °C (CH₃CN). IR (KBr): 1506, 1338, 1164, 1061, 612 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.89 (d, ${}^{4}J$ = 2.1 Hz, 1H), 7.47 $(dd, {}^{4}J = 2.2 \text{ Hz}, {}^{3}J = 8.3 \text{ Hz}, 1\text{H}), 7.33 (d, {}^{3}J = 8.2 \text{ Hz}, 1\text{H}), 7.03 (s, 1\text{H}), 6.81 (s, 1\text{H}), 5.48 (s, 1\text{H}), 7.03 (s, 1\text{H}), 6.81 (s, 1\text{H}), 5.48 (s, 1\text{H}), 6.81 (s, 1$ 1H), 4.23 (m, 2H), 4.21 (m, 2H), 4.18 (m, 1H), 4.10 (m, 1H), 3.74 (m, 1H), 3.56 (m, 1H). ¹³C NMR (125 MHz, CDCl₃): 144.71, 144.18, 144.03, 136.35, 134.31, 133.07, 132.47, 131.44, 130.43, 127.94, 119.70, 117.28, 83.18, 64.29, 64.17, 61.88, 52.62. NOE: 3.74–(7.03, 6.81, 5.48, 4.10, 3.56), 3.56–(7.03, 6.81, 5.48, 4.18, 3.74). COSY: 7.89–7.47–7.33, 4.23–4.21, (4.18, 3.56)-(4.10, 3.74). HSQC (140 Hz): 7.89-127.94, 7.47-132.47, 7.33-133.09, 7.03-119.70, 6.81-117.28, 5.48-83.18, 4.23-64.17, 4.21-64.29, 4.18-52.62, 4.10-61.88, 3.74-61.88, 3.56-6.81-117.2852.62. HMQC (140 Hz, 8 Hz): 7.89–(136.35, 132.47, 131.44), 7.47–(136.35, 131.44, 127.94), 7.33–(144.71, 136.35, 83.18), 7.03–(144.03, 134.31, 130.43), 6.81–(144.18, 130.43, 119.70, 83.18), 5.48–(144.71, 134.31, 130.43, 117.28, 61.88), 4.23–(144.18, 64.29), 4.21–(144.03, 64.17), 4.18-(130.43, 83.18), 4.10-83.18, 3.74-83.18, 3.56-61.88. MS (ESI): $[M+H]^+ = 380$ (1 Cl). HRMS (ESI): m/z calcd. for C₁₇H₁₅ClNO₅S [M+H]⁺: 380.0354, found: 380.0354.

10-Chloro-7-methyl-2,3,7,13-tetrahydro[1,4]benzodioxino[6,5-c]benzo[f][1,2]thiazepin-13-ol 8,8-dioxide (36). To a suspension of 8 (2.23 g, 6.1 mmol) in DMF (15 mL) and EtOH (15 mL), NaBH₄ (0.46 g, 12.2 mmol) was added, and the reaction mixture was stirred at room

temperature for 3 h. To the solution obtained water (150 mL) was added dropwise. The separated product was filtered, washed with water, and dried in vacuo to give **36** (2.00 g, 89%) as colorless crystals. The quality of the rigorously dried compound was suitable for the next reaction step. A sample of **36** (0.65 g) was purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 20 mm, eluent: DCM, DCM/MeOH 100:1). After evaporation of solvents, the oily residue was triturated with DIPE, filtered and dried in vacuo to afford **36** (0.585 g, 84%) as colorless crystals. M. p. decomp. from 155 °C. IR (KBr): 3544, 1490, 1346, 847, 589 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 7.77 (d, 4J = 2.2 Hz, 1H), 7.68 (dd, 4J = 2.3 Hz, 3J = 8.3 Hz, 1H), 7.61 (d, 3J = 8.3 Hz, 1H), 6.99 (d, 3J = 8.5 Hz, 1H), 6.92 (d, 3J = 8.5 Hz, 1H), 6.22 (d, 3J = 4.3 Hz, 1H), 6.14 (d, 3J = 4.2 Hz, 1H), 4.33 (m, 2H), 4.26 (m, 2H), 3.41 (s, 3H). ¹³C NMR (125 MHz, DMSO- d_6): 143.50, 142.88, 140.77, 136.68, 134.35, 133.90, 132.16, 131.50, 130.18, 126.93, 122.62, 117.62, 66.79, 64.51, 63.89, 40.72. MS (EI): [M]⁺ = 367 (1 CI). HRMS (ESI): m/z calcd. for C₁₆H₁₄CINNaO₅S [M+Na]⁺: 390.0173, found: 390.0179.

10,13-Dichloro-7-methyl-2,3,7,13-tetrahydro[1,4]benzodioxino[6,5-

c]benzo[*f*][1,2]thiazepine 8,8-dioxide (37). To a vigorously stirred suspension of 36 (2.39 g, 6.5 mmol) in DCM (25 mL), SOCl₂ (0.93 g, 7.8 mmol, 0.57 mL) was added dropwise at room temperature. The solution obtained was stirred at room temperature for 1.5 h. To the suspension obtained hexane (75 mL) was added, the product was filtered, washed with hexane (2 × 8 mL) and dried in vacuo to give crude 37 (2.36 g, 94%) as colorless crystals. M. p. decomp. from 90 °C. The product was used without purification for the next reaction step. IR (KBr): 1497, 1337, 1161, 1061, 854, 577 cm⁻¹. 1 H NMR (500 MHz, CDCl₃): 7.97 (m, 1H), 7.47 (m, 2H), 7.00 (d, 3 J = 8.7 Hz, 1H), 6.96 (d, 3 J = 8.7 Hz, 1H), 6.72 (s, 1H), 4.20–4.40 (m, 4H), 3.54 (s, 3H). 13 C NMR (125 MHz, CDCl₃): 143.45, 142.21, 140.50, 136.13, 133.43, 133.20, 132.73, 132.25, 127.87, 126.13, 121.52, 119.34, 64.64, 63.79, 53.59, 39.44. MS (EI): [M]⁺ = 385 (2 CI). HRMS (TOF MS EI): m/z calcd. for [C₁₆H₁₃Cl₂NO₄S]⁺: 384.9942, found: 384.9940.

10-Chloro-7-methyl-13-pyrrolidin-1-yl-2,3,7,13-tetrahydro[1,4]benzodioxino[6,5-

c]benzo[f][1,2]thiazepine 8,8-dioxide (38a). To the cooled solution of pyrrolidine (0.106 g, 1.5 mmol) in CH₃CN (2 mL) 37 (0.1785 g, 0.46 mmol) was added. The solution obtained was stirred at room temperature for 1 h. Water (10 mL) was added dropwise, the product separated was filtered, washed with water (2 × 1 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 20 mm, eluent: DCM, DCM/MeOH 100:2). After evaporation of solvents, the residue (0.19 g of colorless oil) was triturated with DIPE (2 mL) to afford 38a (0.153 g, 79%) as colorless crystals. M. p.

decomp. from 213 °C (CH₃CN, bright colorless crystals). IR (KBr): 1491, 1324, 1154, 1109, 1067 cm^{-1} . ¹H NMR (500 MHz, CDCl₃): 7.92 (m, 1H), 7.36 (m, 2H), 6.95 (d, ${}^{3}J = 8.6 \text{ Hz}$, 1H), 6.84 (d, ${}^{3}J = 8.7 \text{ Hz}$, 1H), 4.87 (s, 1H), 4.26 (m, 2H), 4.25 (m, 1H), 4.20 (m, 1H), 3.49 (s, 3H), 2.27 (m, 2H), 2.20 (m, 2H), 1.67 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 143.80, 143.56, 141.29, 135.17, 134.87, 133.62, 131.40, 130.91, 129.94, 128.12, 122.94, 117.69, 64.74, 64.20, 63.91, 53.24 (2C), 40.07, 23.17 (2C). MS (ESI): [M+H]⁺ = 421 (1 Cl). HRMS (ESI): m/z calcd. for $C_{20}H_{22}ClN_2O_4S$ [M+H]⁺: 421.0983, found: 421.0985.

10-Chloro-7-methyl-N-(2-morpholin-4-ylethyl)-2,3,7,13-

tetrahydro[1,4]benzodioxino[6,5-c]benzo[f][1,2]thiazepin-13-amine 8,8-dioxide (38b). To the solution of 4-(2-aminoethyl)morpholine (0.664 g, 5.1 mmol) in CH₃CN (10 mL) 37 (0.608 g, 1.57 mmol) was added. The solution obtained was stirred at room temperature for 1 h. Water (50 mL) was added dropwise in 30 min, the product separated was filtered, washed with water (2 × 5 mL), air-dried and purified by dry-column chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:2). After evaporation of solvents, the residue was triturated with CH₃CN to afford **38b** (0.588 g, 78%) as colorless crystals. M. p. 203–205 °C (CH₃CN). IR (KBr): 3350, 1493, 1313, 1119, 1062 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 7.95 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.42 (dd, ${}^{4}J$ = 2.2 Hz, ${}^{3}J$ = 8.2 Hz, 1H), 6.96 (d, ${}^{3}J = 8.8$ Hz, 1H), 6.87 (d, ${}^{3}J = 8.7$ Hz, 1H), 5.25 (s, 1H), 4.28 (m, 2H), 4.25 (m, 1H), 4.22 (m, 1H), 3.63 (m, 4H), 3.49 (s, 3H), 2.80 (br s, 1H), 2.60 (m, 2H), 2.50 (m, 1H), 2.35 (m, 1H), 2.24 (m, 4H). ¹³C NMR (150 MHz, CDCl₃): 143.32, 142.17, 140.80, 136.04, 134.53, 133.22, 131.56, 131.48, 128.69, 128.20, 120.32, 117.77, 66.81 (2C), 64.37, 63.83, 57.90 (2C), 53.44 (2C), 43.54, 38.51. COSY: 7.95–7.42–7.33, 6.96–6.87, 4.28–(4.25, 4.22), 3.63–2.24, 2.60-(2.50, 2.35). HSQC (140 Hz): 7.95-128.20, 7.42-131.48, 7.33-133.22, 6.96-120.32, 6.87 - 117.77, 5.25 - 57.90, 4.28 - 64.37, 4.25 - 63.83, 4.22 - 63.83, 3.63 - 66.81, 3.49 - 38.51, 2.60 - 60.8143.54, 2.50–57.90, 2.35–57.90, 2.24–53.44. HMBC (8 Hz, 140 Hz): 7.95–(136.04, 134.53, 131.48), 7.42–(136.04, 134.53, 128.20), 7.33–(142.17, 134.53, 57.90), 6.96–(143.32, 128.69), 6.87-(140.83, 131.56), 5.25-(142.17, 140.83, 136.04, 133.22, 131.56, 128.69, 43.54), 4.28-(140.83, 63.83), (4.25, 4.22)-(143.32, 64.37), 3.63-66.81, 3.49-131.56, 2.60-57.90, (2.50, 64.37), 3.63-66.81, 3.49-131.56, 3.49-131.2.35)–(53.44, 43.54), 2.24–53.44. MS (EI): $[M]^+$ = 479 (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₇ClN₃O₅S [M+H]⁺: 480.1354, found: 480.1357.

Ethyl 7-[(10-chloro-7-methyl-8,8-dioxido-2,3,7,13-tetrahydro[1,4]benzodioxino[6,5-c]benzo[f][1,2]thiazepin-13-yl)amino]heptanoate (38c). To a solution of ethyl 7-aminoheptanoate (1.73 g, 10 mmol) in CH₃CN (15 mL) 37 (1.425 g, 3.7 mmol) was added, the solution obtained was stirred at room temperature for 1 h. The solution was evaporated in vacuo,

the oily residue was dissolved in DCM (40 mL), washed with water (2 × 20 mL), dried over Na₂SO₄, and evaporated in vacuo. The oily residue was purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 2:1, 1:1, DCM, DCM/MeOH 100:1). After evaporation of solvents in vacuo **38c** was obtained (1.63 g, 84%) as dense colorless oil which slowly solidified when stored at 5 °C. A small sample (0.20 g) was triturated with a little EtOH to afford **38c** (0.13 g) as colorless crystals. M. p. 81–83 °C. IR (KBr): 3326, 2928, 1726, 1493, 1322, 1146 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.94 (d, 4J = 2.2 Hz, 1H), 7.43 (dd, 4J = 2.2 Hz, 3J = 8.3 Hz, 1H), 7.36 (d, 3J = 8.3 Hz, 1H), 6.93 (d, 3J = 8.7 Hz, 1H), 6.86 (d, 3J = 8.7 Hz, 1H), 5.30 (s, 1H), 4.19-4.33 (m, 4H), 4.11 (q, 3J = 7.2 Hz, 2H), 3.40 (s, 3H), 2.46 (t, 3J = 7.1 Hz, 2H), 2.25 (t, 3J = 7.5 Hz, 2H), 2.02 (br s, 1H), 1.58 (m, 2H), 1.44 (m, 2H), 1.27 (m, 4H), 1.24 (t, 3J = 7.1 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): 173.65, 143.18, 141.91, 141.24, 136.13, 134.41, 133.17, 131.78, 131.67, 128.22, 128.13, 120.44, 117.67, 64.32, 63.83, 60.11, 58.21, 47.79, 38.72, 34.17, 29.75, 28.89, 26.88, 24.77, 14.19. MS (ESI): [M+H]⁺ = 523 (1 Cl). HRMS (ESI): m/z calcd. for C₂₅H₃₂ClN₂O₆S [M+H]⁺: 523.1664, found: 523.1671.

7-[(10-Chloro-7-methyl-8,8-dioxido-2,3,7,13-tetrahydro[1,4]benzodioxino[6,5-

c|benzo[f][1,2]thiazepin-13-yl)amino|heptanoic acid (38d). To a solution of ester 38c (1.41 g, 2.7 mmol) in EtOH (20 mL), NaOH (0.130 g, 3.25 mmol) dissolved in water (5 mL) was added at room temperature and the reaction mixture (gradually diluting suspension, later solution) was stirred at room temperature for 19 h (overnight stirring). Water (15 mL) was added, and the reaction mixture was partly evaporated in vacuo to remove ethanol. The solution obtained was neutralized with aqueous HCl solution (0.27 mL of cc. HCl dissolved in 2.7 mL of water, containing 3.25 mmol of HCl). It was stirred at room temperature for 4 h, the crystalline product obtained was filtered, washed with water (2 × 3 mL), and dried in vacuo to give **38d** (0.804, 60%) as an off-white amorphous solid. Melting range (glass-transition range): 76–85 °C. The aqueous mother liquor was extracted with EtOAc (2 × 20 mL), the combined organic phases were dried over Na₂SO₄, evaporated in vacuo, the residue was triturated with water (2 mL), the wet product was dried in vacuo to give a second crop of 38d (0.30 g, 22%) as an off-white amorphous solid. Melting range (glass-transition range): 76–85 °C. Total yield: 1.10 g, 82%. IR (KBr): 2932, 1713, 1493, 1330, 1109, 1067 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.93 (d, ${}^{4}J$ = 1.5 Hz, 1H), 7.42 (m, 2H), 6.93 (d, ${}^{3}J$ = 8.8 Hz, 1H), 6.88 (d, ${}^{3}J$ = 8.7 Hz, 1H), 6.76 (br s, 2H), 5.43 (s, 1H), 4.28 (m, 3H), 4.23 (m, 1H), 3.38 (s, 3H), 2.50 (m, 2H), 2.18 (t, $^{3}J = 7.3 \text{ Hz}$, 2H), 1.52 (m, 2H), 1.45 (m, 2H), 1.24 (m, 4H). $^{13}\text{C NMR}$ (125 MHz, CDCl₃): 177.84, 143.14, 141.78, 141.31, 134.93, 134.62, 133.69, 131.89, 131.84, 128.10, 126.14, 119.69, 118.08, 64.39, 63.85, 57.33, 47.14, 38.08, 34.44, 28.93, 28.84, 26.83, 24.83. MS (ESI): $[M+H]^+ = 495$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{23}H_{28}ClN_2O_6S$ $[M+H]^+$: 495.1351, found: 495.1355.

Methyl 4-chloro-2-(2,3-dihydro-1,4-benzodioxin-5-ylsulfamoyl)benzoate (39). To a vigorously stirred solution of 2,3-dihydro-1,4-benzodioxin-5-amine (11.50 g, 76 mmol) and N,N-diethylaniline (11.34 g, 76 mmol, 12.1 mL) in MeOH (100 mL), methyl 4-chloro-2chlorosulfonylbenzoate (9, 19.38 g, 72 mmol) was added over a period of 10 min while cooling the reaction mixture with tap water. The suspension formed was stirred at room temperature for 1 h, then at 0-5 °C for 1 h. The crystalline product was filtered and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, DCM). After evaporation of solvents, the solid residue was triturated with MeOH, filtered and air-dried to afford 39 (22.76 g, 82%) as colorless crystals. M. p. 134— 136 °C (MeOH, bright colorless crystals). IR (KBr): 3288, 1727, 1300, 1169, 1087 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 8.30 (br s, 1H), 7.91 (d, ${}^{4}J$ = 2.2 Hz, 1H), 7.81 (d, ${}^{3}J$ = 8.3 Hz, 1H), 7.54 (dd, ${}^{4}J = 2.2 \text{ Hz}$, ${}^{3}J = 8.3 \text{ Hz}$, 1H), 7.15 (dd, ${}^{4}J = 1.5 \text{ Hz}$, ${}^{3}J = 8.2 \text{ Hz}$, 1H), 6.79 (~t, $^{3}J = 8.2 \text{ Hz}$, 1H), 6.66 (dd, $^{4}J = 1.5 \text{ Hz}$, $^{3}J = 8.3 \text{ Hz}$, 1H), 4.10 (m, 2H), 4.01 (s, 3H), 4.00 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): 166.37, 143.50, 140.97, 137.88, 135.52, 132.28, 132.10, 129.89, 128.53, 125.26, 120.82, 115.60, 114.30, 64.28, 63.90, 53.39. MS (ESI): [M-H] = 382 (1 Cl). HRMS (ESI): m/z calcd. for $C_{16}H_{15}CINO_6S$ [M+H]⁺: 384.0303, found: 384.0299.

Methyl 4-chloro-2-[2,3-dihydro-1,4-benzodioxin-5-yl(methyl)sulfamoyl]benzoate (40). To a solution of compound 39 (22.26 g, 58 mmol) in DMF (100 mL), anhydrous K_2CO_3 (10.42 g, 75.4 mmol) was added, and the suspension was stirred at room temperature for 15 min. To the vigorously stirred suspension iodomethane (10.70 g, 75.4 mmol, 4.7 mL) was added dropwise while cooling the reaction mixture with tap water. It was stirred at room temperature for 2 h, then water (500 mL) was added. The oily product separated, the supernatant was decanted, the oil was dissolved in DCM (100 mL), the solution was washed with water (2 × 80 mL), dried over Na₂SO₄ and diluted with heptane (125 mL). Kieselgel 60 H (for TLC, 5–40 μm, 7 g) was added and the mixture was stirred for half an hour. The adsorbent was removed by filtration, and the filtrate was evaporated in vacuo. The residue was triturated with MeOH (50 mL), the product was filtered, washed with MeOH and air-dried to afford 40 (20.00 g, 87%) as bright colorless crystals. M. p. 103–105 °C (MeOH). IR (KBr): 1745, 1477, 1350, 1283, 1117, 1079 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.73 (d, ⁴*J* = 2.0 Hz, 1H), 7.53 (dd, ⁴*J* = 2.1 Hz, ³*J* = 8.2 Hz, 1H), 6.88 (dd, ⁴*J* = 1.7 Hz, ³*J* = 8.2 Hz, 1H), 6.82 (~t, ³*J* = 8.0 Hz, 1H), 4.14 (m, 2H), 3.92 (m, 2H), 3.77 (s, 3H), 3.29 (s,

3H). ¹³C NMR (125 MHz, CDCl₃): 167.48, 144.37, 141.08, 139.11, 135.63, 131.80, 131.51, $129.34, 129.15, 128.32, 123.71, 120.44, 117.65, 64.05, 63.81, 53.06, 38.21. MS (EI): [M]^+ =$ 397 (1 Cl). HRMS (ESI): m/z calcd. for C₁₇H₁₇ClNO₆S [M+H]⁺: 398.0460, found: 398.0461. 4-Chloro-2-[2,3-dihydro-1,4-benzodioxin-5-yl(methyl)sulfamoyl]benzoic acid (41). A solution of NaOH (5.48 g, 137 mmol) in water (100 mL) was added to the suspension of compound 40 (21.80 g, 54.8 mmol) in MeOH (100 mL) and the mixture was refluxed for 1 h. The solution thus obtained was diluted with water (600 mL), aqueous HCl solution (5 m/m %, 100 mL, 105 g, 144 mmol HCl) was added while cooling the reaction mixture with tap water. The sticky oily product separated from the reaction mixture (pH 1) slowly crystallized while stirring at room temperature for 1 h. It was filtered, washed with water (3 × 60 mL), and dried over P₂O₅ to afford crude 41 (20.45 g, 97%) as off-white crystals of suitable quality for next reaction step. M. p. 188–191 °C (CH₃CN, decomp.). IR (KBr): 2883, 1707, 1353, 1303, 1169, 1080, 1060, 979 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 13.57 (br s, 1H), 7.80 (dd, 4J = 2.2 Hz, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.64 (d, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0 \text{ Hz}$, 1H), 6.90 (dd, $^{4}J = 1.8 \text{ Hz}$, $^{3}J = 8.2 \text{ Hz}$, 1H), 7.52 (d, $^{4}J = 2.0$ 8.1 Hz, 1H), 6.83 (\sim t, ^{3}J = 8.0 Hz, 1H), 6.79 (dd, ^{4}J = 2.0 Hz, ^{3}J = 8.1 Hz, 1H), 4.15 (m, 2H), 3.93 (m, 2H), 3.20 (s, 3H). ¹³C NMR (125 MHz, DMSO-*d6*): 168.21, 144.50, 141.21, 137.75, 133.97, 133.44, 132.77, 129.92, 128.49, 128.35, 123.24, 120.39, 117.60, 64.23, 63.83, 38.17. MS (ESI): $[M-H]^- = 382$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{16}H_{15}CINO_6S$ $[M+H]^+$: 384.0303, found: 384.0302.

10-Chloro-13-methyl-2,3-dihydro[1,4]benzodioxino[5,6-c]benzo[f][1,2]thiazepin-7(13H)-one 12,12-dioxide (42). To the thin suspension of **41** (19.80 g, 51.6 mmol) in DCM (165 mL), PCl₅ (12.91 g, 62 mmol, 1.2 equiv) was added in two portions (effervescence!), and the solution obtained was refluxed for 9 h. The solution was cooled to 0–5 °C, and SnCl₄ (29.60 g, 113.5 mmol, 13.3 mL, 2.2 equiv) was added. The suspension obtained was stirred at 0–5 °C for 1.5 h, then it was allowed to warm to room temperature (approx. 1 h). It was diluted with DCM (165 mL), poured onto a mixture of crushed ice (600 g) and conc. hydrochloric acid (85 mL, 100 g, 1 mol of HCl). The crystalline product separated was filtered, washed with diluted hydrochloric acid (5%, 2 × 50 mL) and water (2 × 50 mL), and air-dried to give crude **42** (10.93 g of off-white solid). The two-phase filtrate was separated, the strongly acidic aqueous phase was washed with DCM (100 mL), the combined organic phases were washed with aqueous HCl solution (5 m/m %, 100 mL), dried over Na₂SO₄, evaporated in vacuo, and the residue was triturated with DIPE to afford a second crop of crude **42** (6.88 g of pale pink solid). The two crops combined were purified by dry-column flash chromatography on a short silica gel column (thickness of the stationary phase: 30 mm, eluent: DCM). After evaporation of the

solvent, the residue was triturated with CH₃CN (50 mL) to give pure **42** (16.28 g, 86%) as colorless crystals. M. p. 265–267 °C (CH₃CN/EtOH 1:1). IR (KBr): 1643, 1601, 1578, 1354, 1278, 1170, 1078, 996 cm⁻¹. ¹H NMR (500 MHz, CDCl₃+CD₃OD): 8.01 (d, ${}^{3}J$ = 8.4 Hz, 1H), 7.98 (d, ${}^{4}J$ = 2.1 Hz, 1H), 7.89 (d, ${}^{3}J$ = 9.0 Hz, 1H), 7.70 (dd, ${}^{4}J$ = 2.1 Hz, ${}^{3}J$ = 8.3 Hz, 1H), 6.98 (d, ${}^{3}J$ = 9.0 Hz, 1H), 4.41 (m, 2H), 4.39 (m, 2H), 3.10 (s, 3H). ¹³C NMR (125 MHz, CDCl₃+CD₃OD): 187.60, 149.34, 138.61, 138.50, 137.56, 134.08, 133.85, 133.11, 130.50, 126.43, 125.94, 124.37, 116.27, 64.33, 64.10, 37.74. HSQC (140 Hz): 8.01–133.85, 7.98–126.43, 7.89–124.37, 7.70–133.11, 6.98–116.27, 4.41–64.10, 4.39–64.33, 3.10–37.74. HMQC (140 Hz, 8 Hz): 8.01–(187.60, 138.50, 137.56), 7.98–(138.50, 133.11), 7.89–(187.60, 149.34, 130.50), 7.70–(138.50, 134.08, 126.43), 6.98–(149.34, 138.61, 125.94), 4.41–(138.61, 64.33), 4.39–(149.34, 64.10), 3.10–130.50. MS (EI): [M]⁺ = 365 (1 CI). HRMS (ESI): m/z calcd. for C₁₆H₁₃ClNO₅S [M+H]⁺: 366.0197, found: 366.0200.

10-Chloro-13-methyl-2,3,7,13-tetrahydro[1,4]benzodioxino[5,6-c]benzo[f][1,2]thiazepin-7-ol 12,12-dioxide (43). To a suspension of **42** (5.49 g, 15 mmol) in DMF (30 mL) and EtOH (30 mL), NaBH₄ (1.135 g, 30 mmol) was added, and the reaction mixture was stirred at room temperature for 4.5 h. Water (300 mL) was added dropwise over 30 min. The separated product was filtered, washed with water and Et₂O, and air-dried to give TLC pure crude **43** (5.32 g, 96%) as colorless crystals. M. p. decomp. from 208 °C (CH₃CN/EtOH 1:1). IR (KBr): 3484, 1493, 1304, 1070, 984 cm⁻¹. This compound is a 6:4 mixture of two conformers in DMSO-*d*₆ solution at 25 °C. ¹H NMR (500 MHz, DMSO-*d*₆): 7.92 (m, 0.6H), 7.80–7.65 (m, 2.2H), 7.05–6.98 (d, 1H), 6.96–6.86 (m, 1H), 6.57 (br s, 0.6H), 6.24 (br s, 0.4H), 6.18 (br s, 0.6H), 5.73 (br s, 0.4H), 4.40–4.20 (m, 4H), 3.40–3.20 (m, 3H, overlapped with water signal of DMSO-*d*₆). ¹³C NMR (125 MHz, DMSO-*d*₆): 144.49, 143.49, 141.62, 140.83, 140.00, 138.14, 137.42, 134.06, 133.83, 133.45, 132.53, 132.29, 131.98, 127.06, 126.65 (126.60, shoulder), 122.57, 121.16, 117.54, 116.68, 115.94, 75.41, 65.97, 64.58, 64.08, 40.30, 40.13, 39.96, 39.79, 38.90, 36.02. MS (EI): [M]⁺: 367 (1 Cl). HRMS (ESI): m/z calcd. for C₁₆H₁₄ClNNaO₅S [M+Na]⁺: 390.0173, found: 390.0170.

7,10-Dichloro-13-methyl-2,3,7,13-tetrahydro[1,4]benzodioxino[5,6-

c]benzo[f][1,2]thiazepine 12,12-dioxide (44). To a vigorously stirred suspension of 43 (5.74 g, 15.6 mmol) in DCM (250 mL), SOCl₂ (7.43 g, 62.4 mmol, 4.5 mL, 4 equiv) was added dropwise at room temperature. The suspension was stirred at room temperature for 2 h (no solution was obtained). To the suspension hexane (500 mL) was added, the product was filtered, washed with hexane (2 × 30 mL) and dried in vacuo to give crude 44 (5.65 g, 94%). M. p. decomp. from 250 °C. The compound is of suitable quality for the next step. IR (KBr): 1504,

1477, 1336, 1319, 1160, 670 cm⁻¹. No NMR spectra of **44** could be recorded due to the extremely low solubility of this compound in the usual NMR solvents and their mixtures as well.

10-Chloro-N,13-dimethyl-2,3,7,13-tetrahydro[1,4]benzodioxino[5,6-

c|benzo[f][1,2]thiazepin-7-amine 12,12-dioxide (45a). To the cold solution of methylamine (0.62 g, 20 mmol) in dioxane (15 mL) crude 44 (1.545 g, 4 mmol) was added, and the suspension obtained was stirred at 5-10 °C for 2 h and at room temperature for 1 h. To the thin suspension water (50 mL) was added dropwise, the product precipitated was filtered, washed with water (2 × 5 mL), air-dried and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1, 100:2). After evaporation of solvents, the solid residue was triturated with CH₃CN (5 mL) to afford 45a (1.30 g, 85%) as colorless crystals. M. p. 187–189 °C (CH₃CN). IR (KBr): 3323, 1498, 1327, 1157, 1070 cm⁻¹. This compound is a 16:9 mixture of two conformers in DMSO d_6 solution at 25 °C. At elevated temperature (352 K) the signals of the two species coalesced. ¹H NMR (500 MHz, CDCl₃): 7.77–7.64 (m, 2.2H), 7.58 (d, ^{3}J = 8.4 Hz, 0.64H), 6.93–6.86 (m, 2H), 5.12 (d, ${}^{3}J$ = 8.4 Hz, 0.35H), 4.67 (s, 0.63H), 4.40–4.20 (m, 4H), 3.37 (s, 1.9H), 3.24 (s, 1.06H), 3.01 (m, 0.4H), 2.33 (d, ${}^{3}J$ = 4.4 Hz, 1.1H), 2.28 (br s, 0.64H), 2.09 (br s, 2H). ${}^{13}C$ NMR (125 MHz, CDCl₃): (33 signals) 144.42, 143.28, 143.20, 142.03, 141.41, 140.39, 138.77, 136.87, 134.65, 133.52, 133.31, 132.27, 132.11, 131.72, 128.81, 127.36, 126.51, 126.13, 125.01, 122.58, 117.81, 117.23, 116.79, 70.22, 64.53, 64.51, 64.07, 64.03, 60.40, 38.41, 36.49, 34.90, 34.59. MS (ESI): $[M+H]^+ = 381$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{17}H_{18}ClN_2O_4S$ [M+H]⁺: 381.0670, found: 381.0668.

10-Chloro-13-methyl-7-pyrrolidin-1-yl-2,3,7,13-tetrahydro[1,4]benzodioxino[5,6-

c]benzo[f][1,2]thiazepine 12,12-dioxide (45b). To the solution of pyrrolidine (0.85 g, 12 mmol, 1.0 mL) in CH₃CN (30 mL) crude 44 (1.55 g, 4 mmol) was added. The solution obtained was stirred at room temperature for 1 h. Water (150 mL) was added dropwise, the product separated was filtered, washed with water (3 × 5 mL), air-dried and purified by drycolumn flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1). After evaporation of solvents, the residue was triturated with Et₂O (5 mL) to afford 45b (1.24 g, 74%) as colorless crystals. M. p. 189–191 °C (CH₃CN). IR (KBr): 2937, 1496, 1306, 1153, 1069 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.94 (d, 4J = 2.2 Hz, 1H), 7.35 (dd, 4J = 2.2 Hz, 3J = 8.3 Hz, 1H), 7.29 (d, 3J = 8.3 Hz, 1H), 6.79 (d, 3J = 8.4 Hz, 1H), 6.73 (d, 3J = 8.6 Hz, 1H), 4.37 (m, 1H), 4.35 (m, 1H), 4.28 (m, 2H), 4.04 (s, 1H), 3.42 (s, 3H), 2.21 (m, 2H), 2.14 (m, 2H), 1.67 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 144.58,

143.45, 142.35, 135.64, 134.82, 134.77, 133.05, 130.88, 128.09, 125.66, 121.29, 117.12, 76.53, 64.48, 64.11, 53.65 (2C), 38.11, 23.16 (2C). MS (ESI): $[M+H]^+ = 421$ (1 Cl). HRMS (ESI): m/z calcd. for $C_{20}H_{22}ClN_2O_4S$ $[M+H]^+$: 421.0983, found: 421.0983.

1-(10-Chloro-13-methyl-12,12-dioxido-2,3,7,13-tetrahydro[1,4]benzodioxino[5,6-

c|benzo[f][1,2]thiazepin-7-yl)piperidine-4-carboxamide (45c). To the solution of piperidine-4-carboxamide (isonipecotamide, 1.13 g, 8.8 mmol) in CH₃CN (140 mL) crude 44 (1.545 g, 4 mmol) was added. The suspension obtained was stirred at room temperature for 1 h. Water (300 mL) was added dropwise, the product separated was collected by filtration, washed with water (2 × 10 mL), air-dried and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM/MeOH 100:3). After evaporation of solvents, the solid residue was triturated with CH₃CN (15 mL) to afford 45c (1.60 g, 84%) as colorless crystals. M. p. decomp. from 272 °C (CH₃CN). IR (KBr): 3419, 3198, 1682, 1494, 1307, 1151 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 7.77 (d, ⁴J = 2.2 Hz, 1H), 7.64 (dd, ${}^{4}J$ = 2.2 Hz, J_2 =8.3 Hz, 1H), 7.56 (d, ${}^{3}J$ = 8.4 Hz, 1H), 7.20 (br s, 1H), 6.88 (d, ${}^{3}J$ = 8.4 Hz, 1H), 6.86 (d, ${}^{3}J$ = 8.4 Hz, 1H), 6.72 (br s, 1H), 4.39 (m, 1H), 4.31 (m, 2H), 4.26 (s, 1H), 4.25 (m, 1H), 3.37 (s, 3H), 2.50 (m, 1H), 2.28 (m, 1H), 2.04 (m, 1H), 1.82 (m, 2H), 1.59 (m, 2H), 1.43 (m, 2H). ¹³C NMR (125 MHz, DMSO-*d*₆): 176.52, 144.54, 143.44, 142.54, 135.11, 135.04, 133.95, 133.88, 131.42, 127.31, 125.04, 122.28, 117.11, 75.35, 64.52, 64.07, 52.14, 51.82, 41.57, 38.70, 28.85, 28.38. MS (ESI): $[M+H]^+ = 478$ (1 Cl). HRMS (ESI): m/z calcd. for C₂₂H₂₅ClN₃O₅S [M+H]⁺: 478.1198, found: 478.1201.

10-Chloro-7-methoxy-13-methyl-2,3,7,13-tetrahydro[1,4]benzodioxino[5,6-

c|benzo[*f*][1,2]thiazepine 12,12-dioxide (46). To a suspension of crude 44 (0.309 g, 0.8 mmol) in DCM (3 mL) MeOH (3 mL) was added and the solution obtained in 5 min was stirred at room temperature for further 40 min. The solution was evaporated in vacuo, the residue was subjected to dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: heptane/DCM 1:2, DCM). After evaporation of solvents, the solid residue was triturated with Et₂O to afford 46 (0.233 g, 76%) as colorless crystals. M. p. decomp. from 185 °C (MeOH). IR (KBr): 2937, 1493, 1319, 1302, 1074, 982 cm⁻¹. This compound is a 6:4 mixture of two conformers in CDCl₃ solution at 25 °C. ¹H NMR (500 MHz, CDCl₃): 7.97 (br s, 0.40H), 7.87 (br s, 0.32H), 7.71 (m, 0.43H), 7.48–7.35 (m, 1.5H), 6.85 (m, 2H), 5.75 (br s, 0.43H), 5.00 (br s, 0.55H), 4.42–4.25 (m, 4H), 3.58 (br s, 1.33H), 3.47 (br s, 1.33H), 3.37 (br s, 1.67H), 3.22 (br s, 1.67H). ¹³C NMR (125 MHz, CDCl₃): (31 signals) 145.32, 143.88, 142.60, 142.31, 142.20, 139.96, 137.49, 135.52, 135.30, 133.88, 133.39, 133.26, 131.74, 131.62, 131.13, 128.01, 127.89, 126.21, 125.43, 123.09, 122.14, 118.00,

117.00, 115.42, 87.33, 64.47, 64.11, 58.46, 56.80, 38.31, 35.69. MS (EI): $[M]^+$ = 381 (1 Cl). HRMS (ESI): m/z calcd. for $C_{17}H_{20}ClN_2O_5S$ $[M+NH_4]^+$: 399.0776, found: 399.0775.

Methyl 2-[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)amino]benzoate (48). To the solution of 2,3-dihydro-1,4-benzodioxine-6-sulfonyl chloride (47, 23.47 g, 100 mmol) in pyridine (100 mL) methyl anthranilate (13.61 g, 90 mmol, 11.6 mL) was added at 0—5 °C, and the reaction mixture (suspension after 10 min) was stirred at 0–5 °C for 4 h, then at room temperature for 13 h. Water (600 mL) was added dropwise, the product was filtered, washed with water (3 × 80 mL) to give crude **48** (29.78 g, 95%) as colorless crystals. M. p. 158–160 °C (MeOH). IR (KBr): 3151, 1690, 1499, 1286, 1254, 1154, 1085 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 10.62 (br s, 1H), 7.92 (m, 1H), 7.66 (m, 1H), 7.45 (m, 1H), 7.38 (d, 4J = 2.2 Hz, 1H), 7.34 (dd, 4J = 2.3 Hz, 3J = 8.5 Hz, 1H), 7.03 (m, 1H), 6.86 (d, 3J = 8.5 Hz, 1H), 4.26 (m, 2H), 4.23 (m, 2H), 3.88 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): 168.25, 147.63, 143.40, 140.48, 134.45, 131.72, 131.09, 122.65, 120.96, 118.71, 117.60, 116.86, 115.67, 64.43, 64.03, 52.41. MS (EI): [M]⁺ = 349. HRMS (ESI): m/z calcd. for C₁₆H₁₆NO₆S [M+H]⁺: 350.0693, found: 350.0698.

Methyl 2-[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)(methyl)amino|benzoate (49).

Method A: To a suspension of compound 48 (29.70 g, 85 mmol) in DMF (85 mL), anhydrous K₂CO₃ (15.27 g, 110.5 mmol, 1.3 equiv) was added, and the suspension was stirred at room temperature for 15 min. Iodomethane (15.68 g, 110.5 mmol, 6.9 mL, 1.3 equiv) was added dropwise while cooling the reaction mixture with tap water. The suspension was stirred at room temperature for 22 h. Water (425 mL) was added, the product precipitated was filtered, washed with water, and air-dried to afford crude 49 (30.73 g, 99%) as off-white crystals. The product was of suitable quality for the next reaction step. Method B: To the ice-cooled solution of 2,3dihydro-1,4-benzodioxine-6-sulfonyl chloride (47, 2.35 g, 10 mmol) in abs. pyridine (10 mL) methyl N-methylanthranilate (1.65 g, 10 mmol, 1.47 mL) was added dropwise. The reaction mixture was stirred at 0-5 °C for 2 h, then at room temperature for 17 h (overnight). The suspension obtained was added to an aqueous HCl solution (5 m/m %, 100 mL). The oily product was separated, DCM (50 mL) was added, the phases were separated, the aqueous phase was washed with DCM (40 mL), the combined organic phases were washed with aqueous HCl solution (5 m/m %, 20 mL), dried over Na₂SO₄, and evaporated in vacuo. The residue was purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 30 mm, eluent: heptane/DCM 1:1, DCM, DCM/MeOH 100:1). After evaporation of solvents, the oily residue was triturated with MeOH to afford 49 (2.60 g, 71%) as colorless crystals. M. p. 96–98 °C (MeOH). IR (KBr): 1734, 1496, 1338, 1290, 1255, 1064

cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.83 (dd, ⁴J = 1.8 Hz, ³J = 7.7 Hz, 1H), 7.43 (m, 1H), 7.37 (m, 1H), 7.21 (d, ⁴J = 2.2 Hz, 1H), 7.11 (dd, ⁴J = 2.2 Hz, ³J = 8.5 Hz, 1H), 6.98 (dd, ⁴J = 1.3 Hz, ³J = 7.7 Hz, 1H), 6.90 (d, ³J = 8.6 Hz, 1H), 4.31 (m, 2H), 4.29 (m, 2H), 3.88 (s, 3H), 3.25 (s, 3H). ¹³C NMR (150 MHz, CDCl₃): 166.87, 147.27, 142.32, 140.15, 132.22, 132.12, 130.97, 128.57, 128.02, 121.36, 117.41, 117.16, 64.49, 64.11, 52.36, 38.79. MS (EI): [M]⁺ = 363. HRMS (ESI): m/z calcd. for C₁₇H₁₈NO₆S [M+H]⁺: 364.0849, found: 364.0850.

2-[(2,3-Dihydro-1,4-benzodioxin-6-ylsulfonyl)(methyl)amino|benzoic acid (50). A solution of NaOH (8.46 g, 211.5 mmol) in water (140 mL) was added to the suspension of crude 49 (30.71 g, 84.5 mmol) in MeOH (140 mL) and the mixture was refluxed for 1 h. The solution thus obtained was diluted with water (700 mL), aqueous HCl solution (5 m/m %, 200 mL, 210 g, 288 mmol HCl) was added over 20 min while cooling the reaction mixture with ice water. The sticky oily product separated slowly crystallized while stirring at room temperature for 1 h. It was collected by filtration, washed with water (3 × 60 mL) and dried in vacuo over P₂O₅ to afford crude **50** (29.01 g, 95%) as colorless crystals. M. p. 171–173 °C (CH₃CN, decomp.). The quality of the dried product was suitable for the next reaction step. IR (KBr): 1679, 1496, 1346, 1290, 1062 cm⁻¹. ¹H NMR (600 MHz, DMSO- d_6): 12.94 (br s, 1H), 7.74 (m, 1H), 7.48 (m, 1H), 7.44 (m, 1H), 7.04 (m, 1H), 7.04 (m, 1H), 7.03 (m, 1H), 6.91 (m, 1H), 4.35 (m, 2H), 4.31 (m, 2H), 3.14 (s, 3H). ¹³C NMR (150 MHz, DMSO-d₆): 167.62, 147.54, 143.50, 139.65, 133.66, 132.09, 130.43, 130.35, 128.35, 128.29, 121.13, 117.81, 116.44, 64.64, 64.25, 38.87. COSY: 7.74–7.44–7.48-6.91, 7.04–7.04–7.03, 4.35–4.31. HSQC (140 Hz): 7.74–130.43, 7.48–132.09, 7.44–128.35, 7.04–121.13, 7.04–117.81, 7.03–116.44, 6.91–128.29, 4.35–64.64, 4.31–64.25, 3.14–38.87. HMBC (8 Hz, 140 Hz): 7.74–(167.62, 139.65, 132.09), 7.48–(139.65, 130.43), 7.44–(133.66, 128.29), 7.04–(147.54, 116.44), 7.04–(143.50, 130.35), 7.03–(147.54, 121.13), 6.91-(133.66, 128.35), 4.35-147.54, 4.31-143.50, 3.14-139.65. MS (EI): $[M]^+ = 349$. HRMS (ESI): m/z calcd. for $C_{16}H_{16}NO_6S$ [M+H]⁺: 350.0693, found: 350.0694.

dioxide (51). To the suspension of **50** (17.47 g, 50 mmol) in DCM (250 mL), SOCl₂ (8.93 g, 75 mmol, 5.5 mL) was added and the reaction mixture was refluxed for 8.5 h. The solution obtained was cooled to 0–5 °C, and anhydrous AlCl₃ (10.00 g, 75 mmol) was added. The solution was stirred at 0–5 °C for 1.5 h, then it was refluxed for 3 h. The brown solution was poured onto a mixture of crushed ice (300 g) and diluted aqueous hydrochloric acid (5 m/m %, 100 mL). After the ice melted the phases were separated, the aqueous phase was washed with DCM (100 mL), the combined organic phases were washed with water (100 mL), dried over Na₂SO₄, and evaporated in vacuo. The residue was subjected to dry-column flash

chromatography on a short silica gel column (thickness of the stationary phase: 30 mm, eluent: heptane/DCM 2:1, 1:1, 1:2, DCM, DCM/MeOH 100:1, 100:2). After evaporation of the solvents, the solid residue was triturated with Et₂O (20 mL) to give pure **51** (4.26 g, 26%) as pale yellow crystals. M. p. 194–196 °C (CH₃CN). IR (KBr): 1648, 1350, 1299, 1159, 1066, 894 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 8.29 (m, 1H), 7.61 (m, 1H), 7.55 (s, 1H), 7.48 (s, 1H), 7.36 (m, 1H), 7.34 (m, 1H), 4.36 (m, 2H), 4.34 (m, 2H), 3.30 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): 188.81, 147.09, 146.39, 141.32, 134.49, 132.13, 131.70, 130.42, 129.60, 126.18, 125.32, 121.32, 115.48, 64.63, 64.36, 39.19. NOE: 3.30–(7.48, 7.34). COSY: 8.29–7.36–7.61–7.34, 4.36–4.34. HSQC (140 Hz): 8.29–132.13, 7.61–134.49, 7.55–121.32, 7.48–115.48, 7.36–126.18, 7.34–125.32, 4.36–64.36, 4.34–64.63, 3.30–39.19. HMQC (140 Hz, 8 Hz): 8.29–(188.81, 141.32, 134.49), 7.61–(141.32, 132.13), 7.55–(188.81, 146.39, 130.42), 7.48–(147.09, 129.60), 7.36–(131.70, 125.32), 7.34–(131.70, 126.18), 4.36–(146.39, 64.63), 4.34–(147.09, 64.36), 3.30–141.32. MS (EI): [M]⁺ = 331. HRMS (ESI): m/z calcd. for C₁₆H₁₄NO₅S [M+H]⁺: 332.0587, found: 332.0582.

7-Methyl-2,3,7,12-tetrahydrobenzo[c][1,4]benzodioxino[6,7-f][1,2]thiazepin-12-ol 6,6-

dioxide (52). To a suspension of **51** (4.10 g, 12.4 mmol) in DMF (25 mL) and abs. EtOH (25 mL), NaBH₄ (0.91 g, 24 mmol) was added, and the reaction mixture was stirred at room temperature for 4 h. To the solution obtained water (400 mL) was added dropwise. The product separated was filtered, washed with water, air-dried and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 200:1). After evaporation of solvents, the residue was triturated with DIPE (30 mL) to afford **52** (3.86 g, 93%) as colorless crystals. M. p. decomp. from 180 °C. IR (KBr): 3485, 1570, 1493, 1291, 1134, 1061 cm⁻¹. ¹H NMR (500 MHz, DMSO- d_6): 7.58 (m, 1H), 7.46 (m, 1H), 7.36 (m, 1H), 7.34 (m, 1H), 7.28 (d, 4J = 0.9 Hz, 1H), 7.19 (s, 1H), 6.44 (d, 3J = 5.1 Hz, 1H), 6.18 (d, 3J = 5.1 Hz, 1H), 4.30 (m, 2H), 4.27 (m, 2H), 3.32 (s, 3H). ¹³C NMR (125 MHz, DMSO- d_6): 146.54, 143.21, 142.67, 136.92, 134.90, 129.73, 128.71, 128.04, 127.55, 125.62, 116.13, 114.37, 67.70, 64.75, 64.36, 37.07. MS (EI): [M]⁺ = 333. HRMS (ESI): m/z calcd. for C₁₆H₁₆NO₅S [M+H]⁺: 334.0744, found: 334.0741.

12-Chloro-7-methyl-2,3,7,12-tetrahydrobenzo[*c*][1,4]benzodioxino[6,7-*f*][1,2]thiazepine **6,6-dioxide (53).** To a vigorously stirred suspension of **52** (3.50 g, 10.5 mmol) in DCM (25 mL), SOCl₂ (1.50 g, 12.6 mmol, 0.92 mL) was added dropwise at room temperature. The solution obtained turned to a thick suspension. It was stirred at room temperature for 2 h, then hexane (50 mL) was added, the product was filtered, washed with hexane (2 × 10 mL) and dried in vacuo to give crude **53** (3.50 g, 95%) as colorless crystals. M. p. decomp. from 175 °C. The

product was suitable for the next reaction step without further purification. IR (KBr): 1499, 1325, 1299, 1134, 1064, 926, 890 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.51 (s, 1H), 7.50 (m, 1H), 7.47 (m, 1H), 7.39 (m, 1H), 7.32 (m, 1H), 7.03 (s, 1H), 6.06 (s, 1H), 4.29 (m, 4H), 3.54 (s, 3H). ¹³C NMR (125 MHz, CDCl₃): 146.22, 144.50, 139.38, 137.89, 133.03, 131.16, 129.74, 129.21, 128.57, 128.49, 119.78, 117.25, 64.56, 64.36, 64.15, 38.90. MS (ESI): [M-Cl-OH-H]⁻ = 332, [M+CH₃CN+Na]⁺ = 397 (after a rapid hydrolysis of **53**, compound **52** was detected). HRMS (TOF MS EI): m/z calcd. for [C₁₆H₁₄ClNO₄S]⁺: 351.0332, found: 351.0331.

N,7-Dimethyl-2,3,7,12-tetrahydrobenzo[c][1,4]benzodioxino[6,7-f][1,2]thiazepin-12-

amine 6,6-dioxide (54a). To the solution of methylamine (0.78 g, 25 mmol) in dioxane (23 mL) crude 53 (1.76 g, 5 mmol) was added, and the suspension obtained was stirred at room temperature for 1.5 h. Water (75 mL) was added dropwise, the product separated was filtered, washed with water (2 × 10 mL), air-dried and purified by dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1). After evaporation of solvents, the residue was triturated with DIPE (10 mL), filtered and recrystallized from CH₃CN (9 mL) to afford 54a (1.29 g, 75%) as colorless crystals. M. p. 182–184 °C (CH₃CN). IR (KBr): 3362, 1573, 1494, 1287, 1066, 895, 562 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.51 (s, 1H), 7.39 (m, 1H), 7.32 (m, 2H), 7.26 (m, 1H), 6.96 (s, 1H), 4.78 (s, 1H), 4.29 (m, 2H), 4.27 (m, 2H), 3.27 (s, 3H), 2.35 (s, 3H), 2.30 (br s, 1H). ¹³C NMR (125 MHz, CDCl₃): 146.30, 142.65, 139.19, 138.07, 131.82, 130.47, 130.41, 128.89, 127.50, 127.48, 118.72, 118.30, 67.97, 64.61, 64.20, 38.55, 34.80. MS (ESI): [M+H]⁺ = 347. HRMS (ESI): m/z calcd. for C₁₇H₁₉N₂O₄S [M+H]⁺: 347.1060, found: 347.1060.

7-Methyl-12-pyrrolidin-1-yl-2,3,7,12-tetrahydrobenzo[c][1,4]benzodioxino[6,7-

f][1,2]thiazepine 6,6-dioxide (54b). To the solution of pyrrolidine (0.78 g, 11 mmol) in CH₃CN (15 mL) crude 53 (1.76 g, 5 mmol) was added. The suspension obtained was stirred at room temperature for 1 h. Water (30 mL) was added dropwise, the product separated was filtered, washed with water (2 × 5 mL), air-dried, and purified by dry-column chromatography on a short aluminum oxide column (thickness of stationary phase: 25 mm, eluent: heptane/DCM 1:1, DCM). After evaporation of solvents, the residue was triturated with DIPE (10 mL) to afford TLC-pure 54b (1.53 g, 79%) as colorless crystals. M. p. decomp. from 210 °C (CH₃CN). IR (KBr): 1503, 1311, 1293, 1135, 1066, 562 cm^{-1.1}H NMR (500 MHz, CDCl₃): 7.47 (s, 1H), 7.43 (m, 1H), 7.34 (m, 1H), 7.29 (m, 1H), 7.25 (m, 1H), 6.89 (s, 1H), 4.27 (m, 1H), 4.24 (m, 1H), 4.23 (m, 2H), 4.11 (s, 1H), 3.50 (s, 3H), 2.25 (m, 4H), 1.69 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 145.36, 143.45, 142.18, 138.27, 133.73, 131.56, 130.38, 129.74, 129.51, 128.40,

119.27, 117.50, 75.80, 64.59, 64.21, 53.67 (2C), 39.44, 23.26 (2C). MS (ESI): $[M+H]^+ = 387$. HRMS (ESI): m/z calcd. for $C_{20}H_{23}N_2O_4S$ $[M+H]^+$: 387.1373, found: 387.1376.

7-Methyl-*N*-(2-morpholin-4-ylethyl)-2,3,7,12-tetrahydrobenzo[*c*][1,4]benzodioxino[6,7-

f|[1,2]thiazepin-12-amine 6,6-dioxide (54c). To the solution of 4-(2-aminoethyl)morpholine (1.15 g, 8.8 mmol) in CH₃CN (15 mL) crude 53 (1.41 g, 4 mmol) was added. The suspension formed was stirred at room temperature for 1.5 h. Water (50 mL) was added dropwise, and an oily product separated. Water (20 mL) and DCM (20 mL) were added, and stirring was continued for 10 min. The phases were separated, the aqueous phase was washed with DCM (20 mL), the combined organic phase was washed with water (20 mL), dried over Na₂SO₄, and evaporated in vacuo. The residue was purified by dry-column flash chromatography first on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1, 100:2). After evaporation of solvents, the residue was purified again by dry-column flash chromatography on a short aluminum oxide column (thickness of stationary phase: 25 mm, eluent: heptane/DCM 1:1, 1:2, DCM, DCM/MeOH 100:1). After evaporation of solvents, the residue was crystallized from CH₃CN to afford 54c (1.31 g, 74%) as colorless crystals. M. p. 142–144 °C (CH₃CN). IR (KBr): 3347, 1575, 1333, 1308, 1287, 1118, 1066, 896 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 7.49 (s, 1H), 7.36 (m, 2H), 7.32 (m, 1H), 7.25 (m, 1H), 6.97 (s, 1H), 4.92 (s, 1H), 4.28 (m, 2H), 4.25 (m, 2H), 3.67 (m, 4H), 3.36 (s, 3H), 2.73 (br s, 1H), 2.62 (m, 2H), 2.52 (m, 1H), 2.46 (m, 1H), 2.35 (m, 4H). ¹³C NMR (125 MHz, CDCl₃): 146.21, 142.72, 139.51, 138.84, 132.63, 130.77, 129.33, 128.84, 127.65, 127.40, 118.06, 117.86, 66.87 (2C), 65.39, 64.60, 64.16, 58.19, 53.63 (2C), 44.11, 37.95. MS (EI): $[M]^+ = 445$. HRMS (ESI): m/z cald. for $C_{22}H_{28}N3O_5S$ $[M+H]^+$: 446.1744, found: 446.1740.

7-Methyl-*N*-(3-morpholin-4-ylpropyl)-2,3,7,12-tetrahydrobenzo[*c*][1,4]benzodioxino[6,7-*f*][1,2]thiazepin-12-amine 6,6-dioxide (54d). To the solution of 4-(3-aminopropyl)morpholine (1.27 g, 8.8 mmol) in CH₃CN (15 mL) crude 53 (1.41 g, 4 mmol) was added. The solution obtained was stirred at room temperature for 1 h, then it was evaporated in vacuo. The residue was dissolved in DCM (30 mL), the solution was washed with water (2 × 20 mL), dried over Na₂SO₄, and evaporated in vacuo. The residue was purified by dry-column flash chromatography firstly on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:1, 100:2, 100:3). After evaporation of solvents, the residue was purified again by dry-column flash chromatography on a short aluminum oxide column (thickness of stationary phase: 25 mm, eluent: heptane/DCM 1:1, DCM, DCM/MeOH 100:1). After evaporation of solvents, the residue was triturated with CH₃CN to afford 54d (1.51 g, 82%) as colorless crystals. M. p. 149–151 °C (CH₃CN). IR (KBr): 3354, 1574, 1493, 1333,

1060, 896, 708 cm⁻¹. ¹H NMR (500 MHz, CDCl3): 7.49 (s, 1H), 7.37 (m, 1H), 7.35 (m, 1H), 7.31 (m, 1H), 7.27 (m, 1H), 7.00 (m, 1H), 4.99 (s, 1H), 4.28 (m, 2H), 4.24 (m, 2H), 3.67 (m, 4H), 3.32 (s, 3H), 2.58 (m, 3H), 2.42 (m, 6H), 1.70 (\sim qn, 3J = 6.7 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): 146.32, 142.58, 139.55, 138.83, 132.92, 130.39, 129.07, 128.67, 127.53, 127.35, 118.13, 117.39, 66.88 (2C), 64.59, 64.13, 57.24, 53.71 (2C), 46.61, 37.92, 26.47. MS (ESI): [M+H]⁺ = 460. HRMS (ESI): m/z calcd. for C₂₃H₃₀N₃O₅S [M+H]⁺: 460.1901, found: 460.1896.


Ethyl 7-[(7-methyl-6,6-dioxido-2,3,7,12-tetrahydrobenzo[c][1,4]benzodioxino[6,7-


f[1,2]thiazepin-12-yl)amino|heptanoate (54e). To a solution of ethyl 7-aminoheptanoate (3.47 g, 20 mmol) in CH₃CN (25 mL) crude 53 (3.17 g, 9 mmol) was added which led to a slightly exothermic reaction. The solution obtained was stirred at room temperature for 1 h, then it was evaporated in vacuo. The residue was dissolved in DCM (50 mL), washed with water (2 × 25 mL), dried over Na₂SO₄, and partially evaporated in vacuo. The solution was purified by dry-column flash chromatography on a short aluminum oxide column (thickness of stationary phase: 40 mm, eluent: heptane/DCM 1:1, DCM). After evaporation of solvents in vacuo 54e (4.16 g, 94%) was obtained as a pale yellow oil. IR (film): 2933, 1732, 1574, 1495, 1295, 1068, 895, 712 cm⁻¹. ¹H NMR (600 MHz, CDCl₃): 7.50 (s, 1H), 7.36 (m, 1H), 7.34 (m, 1H), 7.32 (m, 1H), 7.26 (m, 1H), 6.95 (s, 1H), 4.91 (s, 1H), 4.29 (m, 2H), 4.27 (m, 2H), 4.11 $(q, {}^{3}J = 7.1 \text{ Hz}, 2\text{H}), 3.31 \text{ (s, 3H)}, 2.48 \text{ (m, 2H)}, 2.27 \text{ (t, }^{3}J = 7.5 \text{ Hz}, 2\text{H)}, 2.06 \text{ (br s, 1H)}, 1.60$ (m, 2H), 1.49 (m, 2H), 1.31 (m, 2H), 1.30 (m, 2H), 1.24 (t, ${}^{3}J$ = 7.1 Hz, 3H). ${}^{13}C$ NMR (150) MHz, CDCl₃): 173.77, 146.30, 142.65, 138.96 (2C), 132.57, 130.56, 129.85, 128.83, 127.60, 127.48, 118.17 (2C), 65.71, 64.60, 64.17, 60.15, 47.92, 38.27, 34.24, 29.89, 28.96, 26.92, 24.82, 14.22. COSY: 7.36–7.26–7.32–7.34, 4.29–4.27, 4.11–1.24, 2.48–1.49–1.31–1.30–1.60–2.27. HSQC (140 Hz): 7.50–118.17, 7.36–129.85, 7.34–127.48, 7.32–128.83, 7.26–127.60, 6.95– 118.17, 4.91–65.71, 4.29–64.60, 4.27–64.17, 4.11–60.15, 3.31–38.27, 2.48–47.92, 2.27–34.24, 1.60-24.82, 1.49-29.89, 1.31-26.92, 1.30-28.96, 1.24-14.22. HMBC (8 Hz, 140 Hz): 7.50-(146.30, 132.57), 7.36–(138.96, 128.83), 7.34–(138.96, 127.60), 7.32–(138.96, 129.85), 7.26– (138.96, 127.48), 6.95 - (142.65, 130.56), 4.91 - (138.96, 132.57, 130.56, 129.85, 118.17, 47.92),4.29–146.30, 4.27–142.65, 4.11–(173.77, 14.22), 3.31–138.96, 2.27–(173.77, 28.96, 24.82), 1.60-(173.77, 34.24, 28.96, 26.92), 1.49-(47.92, 26.92), 1.31-28.96, 1.30-26.92, 1.24-60.15. HRMS (ESI): m/z calcd. for C₂₅H₃₃N₂O₆S [M+H]⁺: 489.2054, found: 489.2055.


7-[(7-Methyl-6,6-dioxido-2,3,7,12-tetrahydrobenzo[c][1,4]benzodioxino[6,7-


f[1,2]thiazepin-12-yl)amino|heptanoic acid (54f). To a solution of ester 54e (3.91 g, 8 mmol) in EtOH (40 mL), NaOH (0.384 g, 9.6 mmol) dissolved in water (10 mL) was added at room temperature and the solution was stirred at room temperature for 20 h. Water (30 mL) was


added, and the reaction mixture was partly evaporated in vacuo to remove ethanol. The solution obtained was neutralized with aqueous HCl solution (1.00 g of cc. HCl dissolved in 9 mL of water, containing 10 mmol of HCl). DCM (50 mL) was added to the reaction mixture, after a short stirring the phases were separated, the aqueous phase was washed with DCM (50 mL), the combined organic phases were dried over Na₂SO₄ and partially evaporated in vacuo. The solution obtained was subjected to dry-column flash chromatography on a short silica gel column (thickness of stationary phase: 25 mm, eluent: DCM, DCM/MeOH 100:2, 100:4). After evaporation of solvents the oily residue was triturated with water (40 mL) to afford 54f (2.58 g, 70%) as a colorless amorphous solid. Melting range (glass-transition range): 80–95 °C (Kofler– Boëtius, 2 °C/min), 63-84 °C (DSC, 10 °C/min). IR (KBr): 2931, 1716, 1500, 1296, 1137, 1064 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): 8.10 (br s, 2H), 7.49 (s, 1H), 7.47 (m, 1H), 7.34 (m, 1H), 7.30 (m, 1H), 7.24 (m, 1H), 7.07 (s, 1H), 5.23 (s, 1H), 4.28 (m, 4H), 3.21 (s, 3H), 2.55 (m, 1H), 2.41 (m, 1H), 2.20 (t, ${}^{3}J$ = 7.3 Hz, 2H), 1.54 (m, 2H), 1.48 (m, 2H), 1.25 (m, 4H). ${}^{13}C$ NMR (125 MHz, CDCl₃): 178.16, 146.61, 143.19, 139.78, 134.16, 131.69, 130.39, 129.64, 128.82, 127.40, 127.14, 120.35, 118.13, 65.58, 64.51, 64.20, 46.82, 38.83, 35.16, 28.93, 28.58, 26.79, 25.12. MS (ESI): $[M+H]^+ = 461$. HRMS (ESI): m/z calcd. for $C_{23}H_{29}N_2O_6S$ $[M+H]^+$: 461.1741, found: 461.1739.



























GHSQC_DA (140 Hz) 53958 1732-BGE Berecz Gabor 2004.06.04. (DA) Pulse Sequence: ghsqc_da Solvent: CDC13 Temp. 25.0 C / 298.1 K INOVA-500 "i500"


| INOVA-508 | "1500" sec Acq. time 0.088 sec A


8


GHMOC_DA (140 Hz, 8 Hz)
53858
1732-BGE
Berecz Gabor
2004.06.04. (DA)
Pulse Sequence: ghmqc_da
Solvent: CDC13
Temp. 25.0 C / 298.1 K
INOVA-500 "1500"


Relax. delay 1.500 sec Acq. time 0.080 sec Vidth 5219.9 Hz 20 Width 26367.8 Hz 4 repetitions 256 increments 005KRVE H1, 199.5244681 MHz DHA PROCESSING SING SEC 11 DATA PROCESSING SING bell 0.002 sec FT 15TE 20648 x 512 Total time 29 min, 9 sec



































































































































































notate (Ctri+J)



































OHSOC_DA (140 Hz)
74867
2188-BCE
2188-BCE
2188-BCE
2088.07.02. (DA)
SOIVENT: CDCI3
TEMP. 30.0 C / 303.1 K
INVOA-500 "1500"
PULSE SCUULVECT: phsqc_da
Acq. time 0.187 sec
Acq. time 0.187 sec
Width 28076.1 Hz
20 Vieth 2804.6 Hz
20 Vieth 2804.6 Hz
20 Vieth 2804.5 Hz
20 Vieth 2804.5








OHMOC_DA (140 Hz, 8 Hz)
74867-RGE
74867-RGE
88-RGE 2080-RGE 2080-R





















































































CHSOC_DA (140 Hz)

\$4124


1978-BGE
Berecz Gabor
2006.06.29. (BT)
Solvent: COCI3
Temp. 25.0 C / 298.1 K
INOVA-500 "1500"


PULSE SEQUENCE: ghsqc_da
Relax. delay 1.500 sec
Acq. time 0.205 sec
Width 5002.2 Hz
2 repetitions
2 x 256 increments
0BSERVE H1, 499.5244235 MHz
DECOUPLE Cl3, 125.6174312 MHz
Power 42 dB
off during delay
GARP-I modulated
DATA PROCESSING
Gauss apodization 0.095 sec
F1 DATA PROCESSING
Gauss apodization 0.015 sec
F1 DATA PROCESSING








GHHOC_DA (140Hz, 8Hz)
54124
1778-80E
1478-80E
14






































GMOFCOPS_DA
57266
1831-BGE
Berecz Gabor
2003.03.24. (DA)
SOlvents (DC03.
SOlvents (DC03.
INOVA-500 "1500"
SEQUENCE: gmafcops da
Relax. delay 1.500 sec
Acq. time 0.128 sec
Width 8000.0 Hz
2 22 256 Gorrements
OBSERVE H1, 499.5244665 NHz
DATA PROCESSING
Sq. sine bell 0.128 sec
Shifted by -0.042 sec
Shifted by -0.042 sec
Shifted by -0.042 sec
Shifted by -0.042 sec
Fi Size Apole Shift Shifted Shifted

GHS0C_DA (140 Hz)
572661831-80E
Berecz Gabor
2005.03.24. (DA)
Solvent: CDC13
Temp. 25.0 C / 298.1 K
INOVA-500 "1500"
PULSE SCOUENCE: ghsqc_da
Relax. delay 1500 sec
Width 8000.0 Hz
2D Width 26507.6 Hz
2 repetitions
2 x 255 increments
2 x 255 increments
2 x 256 increments
3 x 356 increments
4 x 300.0 Hz
2 repetitions
2 x 256 increments
2 x 356 increments
3 x 356 increments
4 x 356 increments
2 x 356 increments
3 x 356 increments
3 x 356 increments
4 x 356 increments
3 x 356 increments
4 x 356 increments
5 x 356 increment

